Skip to main content
Erschienen in: Drugs 6/2009

01.04.2009 | Review Article

Community-Associated Meticillin-Resistant Staphylococcus aureus Infections

Epidemiology, Recognition and Management

verfasst von: Dr Mukesh Patel

Erschienen in: Drugs | Ausgabe 6/2009

Einloggen, um Zugang zu erhalten

Abstract

Meticillin-resistant Staphylococcus aureus (MRSA) is an important cause of infection, particularly in hospitalized patients and those with significant healthcare exposure. In recent years, epidemic community-associated MRSA (CA-MRSA) infections occurring in patients without healthcare risk factors have become more frequent. The most common manifestation of CA-MRSA infection is skin and soft tissue infection, although necrotizing pneumonia, sepsis and osteoarticular infections can occur. CA-MRSA strains have become endemic in many communities and are genetically distinct from previously identified MRSA strains. CA-MRSA may be more capable colonizers of humans and more virulent than other S. aureus strains. Specific mechanisms of pathogenicity have not been elucidated, but several factors have been proposed as responsible for the virulence of CA-MRSA, including the Panton-Valentine leukocidin, phenol-soluble modulins and type I arginine catabolic mobile element. The movement of CA-MRSA strains into the nosocomial setting limits the utility of using clinical risk factors alone to designate community- or healthcare-associated status. Identification of unique genetic characteristics and genotyping are valuable tools for MRSA epidemiological studies. Although the optimum pharmacological therapy for CA-MRSA infections has not been determined, many CA-MRSA strains remain broadly susceptible to several non-β-lactam antibacterial agents. Empirical antibacterial therapy should include an MRSA-active agent, particularly in areas where CA-MRSA is endemic.
Literatur
1.
Zurück zum Zitat National Nosocomial Infections Surveillance (NNIS) System Report data summary from January 1992 through June 2004 issued October 2004. Am J Infect Control 2004; 32: 470–85 National Nosocomial Infections Surveillance (NNIS) System Report data summary from January 1992 through June 2004 issued October 2004. Am J Infect Control 2004; 32: 470–85
2.
Zurück zum Zitat Noskin GA, Rubin RJ, Schentag JJ, et al. National trends in Staphylococcus aureus infection rates: impact on economic burden and mortality over a 6-year period (1998–2003). Clin Infect Dis 2007; 45: 1132–40PubMedCrossRef Noskin GA, Rubin RJ, Schentag JJ, et al. National trends in Staphylococcus aureus infection rates: impact on economic burden and mortality over a 6-year period (1998–2003). Clin Infect Dis 2007; 45: 1132–40PubMedCrossRef
3.
Zurück zum Zitat Klevens RM, Morrison MA, Nadle J, et al. Invasive methicillin-resistant Staphylococcus aureus infections in the United States. JAMA 2007; 298: 1763–71PubMedCrossRef Klevens RM, Morrison MA, Nadle J, et al. Invasive methicillin-resistant Staphylococcus aureus infections in the United States. JAMA 2007; 298: 1763–71PubMedCrossRef
4.
Zurück zum Zitat Jevons MP, Coe AW, Parker MT. Methicillin resistance in staphylococci. Lancet 1963; I: 904–7CrossRef Jevons MP, Coe AW, Parker MT. Methicillin resistance in staphylococci. Lancet 1963; I: 904–7CrossRef
5.
Zurück zum Zitat Naimi TS, LeDell KH, Como-Sabetti K, et al. Comparison of community and health care-associated methicillinresistant Staphylococcus aureus infection. JAMA 2003; 290: 2976–84PubMedCrossRef Naimi TS, LeDell KH, Como-Sabetti K, et al. Comparison of community and health care-associated methicillinresistant Staphylococcus aureus infection. JAMA 2003; 290: 2976–84PubMedCrossRef
6.
Zurück zum Zitat Levine DP, Cushing RD, Jui J, et al. Community-acquired methicillin-resistant Staphylococcus aureus endocarditis in the Detroit Medical Center. Ann Intern Med 1982; 97: 330–8PubMed Levine DP, Cushing RD, Jui J, et al. Community-acquired methicillin-resistant Staphylococcus aureus endocarditis in the Detroit Medical Center. Ann Intern Med 1982; 97: 330–8PubMed
7.
Zurück zum Zitat Cafferkey MT, Hone R, Falkiner FR, et al. Gentamicin and methicillin-resistant Staphylococcus aureus in Dublin hospitals: clinical and laboratory studies. J Med Microbiol 1983; 16: 117–27PubMedCrossRef Cafferkey MT, Hone R, Falkiner FR, et al. Gentamicin and methicillin-resistant Staphylococcus aureus in Dublin hospitals: clinical and laboratory studies. J Med Microbiol 1983; 16: 117–27PubMedCrossRef
8.
Zurück zum Zitat Udo EE, Pearman JW, Grubb WB. Genetic analysis of community isolates of methicillin-resistant Staphylococcus aureus in Western Australia. J Hosp Infect 1993; 25: 97–108PubMedCrossRef Udo EE, Pearman JW, Grubb WB. Genetic analysis of community isolates of methicillin-resistant Staphylococcus aureus in Western Australia. J Hosp Infect 1993; 25: 97–108PubMedCrossRef
9.
Zurück zum Zitat Herold BC, Immergluck LC, Maranan MC, et al. Community-acquired methicillin-resistant Staphylococcus aureus in children with no identified predisposing risk. JAMA 1998; 279: 593–8PubMedCrossRef Herold BC, Immergluck LC, Maranan MC, et al. Community-acquired methicillin-resistant Staphylococcus aureus in children with no identified predisposing risk. JAMA 1998; 279: 593–8PubMedCrossRef
10.
Zurück zum Zitat Centers for Disease Control and Prevention. Four pediatric deaths from community-acquired methicillin-resistant Staphylococcus aureus — Minnesota and North Dakota, 1997–1999. MMWR Morb Mortal Wkly Rep 1999; 48: 707–10 Centers for Disease Control and Prevention. Four pediatric deaths from community-acquired methicillin-resistant Staphylococcus aureus — Minnesota and North Dakota, 1997–1999. MMWR Morb Mortal Wkly Rep 1999; 48: 707–10
11.
Zurück zum Zitat Centers for Disease Control and Prevention. Methicillinresistant Staphylococcus aureus skin or soft tissue infections in a state prison — Mississippi, 2000. MMWR Morb Mortal Wkly Rep 2001; 50: 919–22 Centers for Disease Control and Prevention. Methicillinresistant Staphylococcus aureus skin or soft tissue infections in a state prison — Mississippi, 2000. MMWR Morb Mortal Wkly Rep 2001; 50: 919–22
12.
Zurück zum Zitat Centers for Disease Control and Prevention. Outbreaks of community-acquired methicillin-resistant Staphylococcus aureus skin infections — Los Angeles County, California, 2002–2003 [letter]. MMWR Morb Mortal Wkly Rep 2003; 52: 88 Centers for Disease Control and Prevention. Outbreaks of community-acquired methicillin-resistant Staphylococcus aureus skin infections — Los Angeles County, California, 2002–2003 [letter]. MMWR Morb Mortal Wkly Rep 2003; 52: 88
13.
Zurück zum Zitat Centers for Disease Control and Prevention. Methicillinresistant Staphylococcus aureus infections in correctional facilities — Georgia, California, and Texas, 2001–2003. MMWR Morb Mortal Wkly Rep 2003; 52: 992–6 Centers for Disease Control and Prevention. Methicillinresistant Staphylococcus aureus infections in correctional facilities — Georgia, California, and Texas, 2001–2003. MMWR Morb Mortal Wkly Rep 2003; 52: 992–6
14.
Zurück zum Zitat Baggett HC, Hennessy TW, Leman RL, et al. Outbreak of community-onset methicillin-resistant Staphylococcus aureus skin infections in southwestern Alaska. Infect Control Hosp Epidemiol 2003; 24: 397–402PubMedCrossRef Baggett HC, Hennessy TW, Leman RL, et al. Outbreak of community-onset methicillin-resistant Staphylococcus aureus skin infections in southwestern Alaska. Infect Control Hosp Epidemiol 2003; 24: 397–402PubMedCrossRef
15.
Zurück zum Zitat Centers for Disease Control and Prevention. Methicillinresistant Staphylococcus aureus infections among competitive sports participants — Colorado, Indiana, Pennsylvania, and Los Angeles County, 2000–2003. MMWR Morb Mortal Wkly Rep 2003; 52: 793–5 Centers for Disease Control and Prevention. Methicillinresistant Staphylococcus aureus infections among competitive sports participants — Colorado, Indiana, Pennsylvania, and Los Angeles County, 2000–2003. MMWR Morb Mortal Wkly Rep 2003; 52: 793–5
16.
Zurück zum Zitat Begier EM, Frenette K, Barrett NL, et al. A high-morbidity outbreak of methicillin-resistant Staphylococcus aureus among players on a college football team, facilitated by cosmetic body shaving and turf burns. Clin Infect Dis 2004; 39: 1446–53PubMedCrossRef Begier EM, Frenette K, Barrett NL, et al. A high-morbidity outbreak of methicillin-resistant Staphylococcus aureus among players on a college football team, facilitated by cosmetic body shaving and turf burns. Clin Infect Dis 2004; 39: 1446–53PubMedCrossRef
17.
Zurück zum Zitat Kazakova SV, Hageman JC, Matava M, et al. A clone of methicillin-resistant Staphylococcus aureus among professional football players. N Engl J Med 2005; 352: 468–75PubMedCrossRef Kazakova SV, Hageman JC, Matava M, et al. A clone of methicillin-resistant Staphylococcus aureus among professional football players. N Engl J Med 2005; 352: 468–75PubMedCrossRef
18.
Zurück zum Zitat Campbell KM, Vaughn AF, Russell KL, et al. Risk factors for community-acquired methicillin-resistant Staphylococcus aureus infections in an outbreak of disease among military trainees in San Diego, California, in 2002. J Clin Microbiol 2004; 42: 4050–3PubMedCrossRef Campbell KM, Vaughn AF, Russell KL, et al. Risk factors for community-acquired methicillin-resistant Staphylococcus aureus infections in an outbreak of disease among military trainees in San Diego, California, in 2002. J Clin Microbiol 2004; 42: 4050–3PubMedCrossRef
19.
Zurück zum Zitat Nimmo GR, Schooneveldt J, O’Kane G, et al. Community acquisition of gentamicin-sensitive methicillin-resistant Staphylococcus aureus in southeast Queensland, Australia. J Clin Microbiol 2000; 38: 3926–31PubMed Nimmo GR, Schooneveldt J, O’Kane G, et al. Community acquisition of gentamicin-sensitive methicillin-resistant Staphylococcus aureus in southeast Queensland, Australia. J Clin Microbiol 2000; 38: 3926–31PubMed
20.
Zurück zum Zitat Aires de Sousa M, Bartzavali C, Spiliopoulou I, et al. Two international methicillin-resistant Staphylococcus aureus clones endemic in a university hospital in Patras, Greece. J Clin Microbiol 2003; 41: 2027–32CrossRef Aires de Sousa M, Bartzavali C, Spiliopoulou I, et al. Two international methicillin-resistant Staphylococcus aureus clones endemic in a university hospital in Patras, Greece. J Clin Microbiol 2003; 41: 2027–32CrossRef
21.
Zurück zum Zitat Vandenesch F, Naimi T, Enright MC, et al. Communityacquired methicillin-resistant Staphylococcus aureus carrying Panton-Valentine leukocidin genes: worldwide emergence. 2003; 9: 978–84 Vandenesch F, Naimi T, Enright MC, et al. Communityacquired methicillin-resistant Staphylococcus aureus carrying Panton-Valentine leukocidin genes: worldwide emergence. 2003; 9: 978–84
22.
Zurück zum Zitat Liassine N, Auckenthaler R, Descombes MC, et al. Community-acquired methicillin-resistant Staphylococcus aureus isolated in Switzerland contains the Panton-Valentine leukocidin or exfoliative toxin genes. J Clin Microbiol 2004; 42: 825–8PubMedCrossRef Liassine N, Auckenthaler R, Descombes MC, et al. Community-acquired methicillin-resistant Staphylococcus aureus isolated in Switzerland contains the Panton-Valentine leukocidin or exfoliative toxin genes. J Clin Microbiol 2004; 42: 825–8PubMedCrossRef
23.
Zurück zum Zitat Velazquez-Meza ME, Aires de Sousa M, Echaniz-Aviles G, et al. Surveillance of methicillin-resistant Staphylococcus aureus in a pediatric hospital in Mexico City during a 7-year period (1997–2003): clonal evolution and impact of infection control. J Clin Microbiol 2004; 42: 3877–80PubMedCrossRef Velazquez-Meza ME, Aires de Sousa M, Echaniz-Aviles G, et al. Surveillance of methicillin-resistant Staphylococcus aureus in a pediatric hospital in Mexico City during a 7-year period (1997–2003): clonal evolution and impact of infection control. J Clin Microbiol 2004; 42: 3877–80PubMedCrossRef
24.
Zurück zum Zitat Ribeiro A, Dias C, Silva-Carvalho MC, et al. First report of community-acquired methicillin-resistant Staphylococcus aureus in South America. J Clin Microbiol 2005; 43: 1985–8PubMedCrossRef Ribeiro A, Dias C, Silva-Carvalho MC, et al. First report of community-acquired methicillin-resistant Staphylococcus aureus in South America. J Clin Microbiol 2005; 43: 1985–8PubMedCrossRef
25.
Zurück zum Zitat Fridkin SK, Hageman JC, Morrison M, et al. Methicillinresistant Staphylococcus aureus disease in three communities. N Engl JMed 2005; 352: 1436–44CrossRef Fridkin SK, Hageman JC, Morrison M, et al. Methicillinresistant Staphylococcus aureus disease in three communities. N Engl JMed 2005; 352: 1436–44CrossRef
26.
Zurück zum Zitat Vourli S, Perimeni D, Makri A, et al. Community acquired MRSA infections in a paediatric population in Greece. Euro Surveill 2005; 10: 78–9PubMed Vourli S, Perimeni D, Makri A, et al. Community acquired MRSA infections in a paediatric population in Greece. Euro Surveill 2005; 10: 78–9PubMed
27.
Zurück zum Zitat Moran GJ, Krishnadasan A, Gorwitz RJ, et al. Methicillinresistant S. aureus infections among patients in the emergency department. N Engl J Med 2006; 355: 666–74PubMedCrossRef Moran GJ, Krishnadasan A, Gorwitz RJ, et al. Methicillinresistant S. aureus infections among patients in the emergency department. N Engl J Med 2006; 355: 666–74PubMedCrossRef
28.
Zurück zum Zitat Hsu LY, Koh YL, Chlebicka NL, et al. Establishment of ST30 as the predominant clonal type among communityassociated methicillin-resistant Staphylococcus aureus isolates in Singapore. J Clin Microbiol 2006; 44: 1090–3PubMedCrossRef Hsu LY, Koh YL, Chlebicka NL, et al. Establishment of ST30 as the predominant clonal type among communityassociated methicillin-resistant Staphylococcus aureus isolates in Singapore. J Clin Microbiol 2006; 44: 1090–3PubMedCrossRef
29.
Zurück zum Zitat Huang YC, Su LH, Wu TL, et al. Changing molecular epidemiology of methicillin-resistant Staphylococcus aureus bloodstream isolates from a teaching hospital in Northern Taiwan. J Clin Microbiol 2006; 44: 2268–70PubMedCrossRef Huang YC, Su LH, Wu TL, et al. Changing molecular epidemiology of methicillin-resistant Staphylococcus aureus bloodstream isolates from a teaching hospital in Northern Taiwan. J Clin Microbiol 2006; 44: 2268–70PubMedCrossRef
30.
Zurück zum Zitat Nimmo GR, Coombs GW, Parson JC, et al. Methicillinresistant Staphylococcus aureus in the Australian community: an evolving epidemic. Med J Aust 2006; 184: 374–5 Nimmo GR, Coombs GW, Parson JC, et al. Methicillinresistant Staphylococcus aureus in the Australian community: an evolving epidemic. Med J Aust 2006; 184: 374–5
31.
Zurück zum Zitat Kuehnert MJ, Kruszon-Moran D, Hill HA, et al. Prevalence of Staphylococcus aureus nasal colonization in the United States, 2001–2002. J Infect Dis 2006; 193: 172–9PubMedCrossRef Kuehnert MJ, Kruszon-Moran D, Hill HA, et al. Prevalence of Staphylococcus aureus nasal colonization in the United States, 2001–2002. J Infect Dis 2006; 193: 172–9PubMedCrossRef
32.
Zurück zum Zitat Gorwitz RJ, Kruszon-Moran D, McAllister SK, et al. Changes in the prevalence of nasal colonization with Staphylococcus aureus in the United States, 2001–2004. J Infect Dis 2008; 197: 1226–34PubMedCrossRef Gorwitz RJ, Kruszon-Moran D, McAllister SK, et al. Changes in the prevalence of nasal colonization with Staphylococcus aureus in the United States, 2001–2004. J Infect Dis 2008; 197: 1226–34PubMedCrossRef
33.
Zurück zum Zitat Eveillard M, de Lassence A, Lancien E, et al. Evaluation of a strategy of screening multiple anatomical sites for methicillin-resistant Staphylococcus aureus at admission to a teaching hospital. Infect Control Hosp Epidemiol 2006; 27: 181–4PubMedCrossRef Eveillard M, de Lassence A, Lancien E, et al. Evaluation of a strategy of screening multiple anatomical sites for methicillin-resistant Staphylococcus aureus at admission to a teaching hospital. Infect Control Hosp Epidemiol 2006; 27: 181–4PubMedCrossRef
34.
Zurück zum Zitat Mertz D, Frei R, Jaussi B, et al. Throat swabs are necessary to reliably detect carriers of Staphylococcus aureus. Clin Infect Dis 2007; 45: 475–7PubMedCrossRef Mertz D, Frei R, Jaussi B, et al. Throat swabs are necessary to reliably detect carriers of Staphylococcus aureus. Clin Infect Dis 2007; 45: 475–7PubMedCrossRef
35.
Zurück zum Zitat Buehlmann M, Frei R, Fenner L, et al. Highly effective regimen for decolonization of methicillin-resistant Staphylococcus aureus carriers. Infect Control Hosp Epidemiol 2008; 29: 510–6PubMedCrossRef Buehlmann M, Frei R, Fenner L, et al. Highly effective regimen for decolonization of methicillin-resistant Staphylococcus aureus carriers. Infect Control Hosp Epidemiol 2008; 29: 510–6PubMedCrossRef
36.
Zurück zum Zitat Roghmann MC, Siddiqui A, Plaisance K, et al. MRSA colonization and the risk of MRSA bacteraemia in hospitalized patients with chronic ulcers. J Hosp Infect 2001; 47: 98–103PubMedCrossRef Roghmann MC, Siddiqui A, Plaisance K, et al. MRSA colonization and the risk of MRSA bacteraemia in hospitalized patients with chronic ulcers. J Hosp Infect 2001; 47: 98–103PubMedCrossRef
37.
Zurück zum Zitat Huang SS, Platt R. Risk of methicillin-resistant Staphylococcus aureus infection after previous infection or colonization. Clin Infect Dis 2003; 36: 281–5PubMedCrossRef Huang SS, Platt R. Risk of methicillin-resistant Staphylococcus aureus infection after previous infection or colonization. Clin Infect Dis 2003; 36: 281–5PubMedCrossRef
38.
Zurück zum Zitat Davis KA, Stewart JJ, Crouch HK, et al. Methicillinresistant Staphylococcus aureus (MRSA) nares colonization at hospital admission and its effect on subsequent MRSA infection. Clin Infect Dis 2004; 39: 776–82PubMedCrossRef Davis KA, Stewart JJ, Crouch HK, et al. Methicillinresistant Staphylococcus aureus (MRSA) nares colonization at hospital admission and its effect on subsequent MRSA infection. Clin Infect Dis 2004; 39: 776–82PubMedCrossRef
39.
Zurück zum Zitat Ellis MW, Hospenthal DR, Dooley DP, et al. Natural history of community-acquired methicillin-resistant Staphylococcus aureus colonization and infection in soldiers. Clin Infect Dis 2004; 39: 971–9PubMedCrossRef Ellis MW, Hospenthal DR, Dooley DP, et al. Natural history of community-acquired methicillin-resistant Staphylococcus aureus colonization and infection in soldiers. Clin Infect Dis 2004; 39: 971–9PubMedCrossRef
40.
Zurück zum Zitat Cohen AL, Shuler C, McAllister S, et al. Methamphetamine use and methicillin-resistant Staphylococcus aureus skin infections. Emerg Infect Dis 2007; 13: 1707–13PubMedCrossRef Cohen AL, Shuler C, McAllister S, et al. Methamphetamine use and methicillin-resistant Staphylococcus aureus skin infections. Emerg Infect Dis 2007; 13: 1707–13PubMedCrossRef
41.
Zurück zum Zitat Diep BA, Chambers HF, Graber CJ, et al. Emergence of multidrug-resistant, community-associated, methicillinresistant Staphylococcus aureus clone USA300 in men who have sex with men. Ann Intern Med 2008; 148: 249–57PubMed Diep BA, Chambers HF, Graber CJ, et al. Emergence of multidrug-resistant, community-associated, methicillinresistant Staphylococcus aureus clone USA300 in men who have sex with men. Ann Intern Med 2008; 148: 249–57PubMed
42.
Zurück zum Zitat Groom AV, Wolsey DH, Naimi TS, et al. Communityacquired methicillin-resistant Staphylococcus aureus in a rural American Indian community. JAMA 2001; 286: 1201–5PubMedCrossRef Groom AV, Wolsey DH, Naimi TS, et al. Communityacquired methicillin-resistant Staphylococcus aureus in a rural American Indian community. JAMA 2001; 286: 1201–5PubMedCrossRef
43.
Zurück zum Zitat Baggett HC, Hennessy TW, Rudolph K, et al. Communityonset methicillin-resistant Staphylococcus aureus associated with antibiotic use and the cytotoxin Panton-Valentine leukocidin during a furunculosis outbreak in rural Alaska. J Infect Dis 2004; 189: 1565–73PubMedCrossRef Baggett HC, Hennessy TW, Rudolph K, et al. Communityonset methicillin-resistant Staphylococcus aureus associated with antibiotic use and the cytotoxin Panton-Valentine leukocidin during a furunculosis outbreak in rural Alaska. J Infect Dis 2004; 189: 1565–73PubMedCrossRef
44.
Zurück zum Zitat McDougal LK, Steward CD, Killgore GE, et al. Pulsedfield gel electrophoresis of oxacillin-resistant Staphylococcus aureus isolates from the United States: establishing a national database. J Clin Microbiol 2003; 41: 5113–20PubMedCrossRef McDougal LK, Steward CD, Killgore GE, et al. Pulsedfield gel electrophoresis of oxacillin-resistant Staphylococcus aureus isolates from the United States: establishing a national database. J Clin Microbiol 2003; 41: 5113–20PubMedCrossRef
45.
Zurück zum Zitat Diep BA, Carleton HA, Chang RF, et al. Role of 34 virulence genes in the evolution of hospital- and communityassociated strains of methicillin-resistant Staphylococcus aureus. J Infect Dis 2006; 193: 1495–503PubMedCrossRef Diep BA, Carleton HA, Chang RF, et al. Role of 34 virulence genes in the evolution of hospital- and communityassociated strains of methicillin-resistant Staphylococcus aureus. J Infect Dis 2006; 193: 1495–503PubMedCrossRef
46.
Zurück zum Zitat Baba T, Takeuchi F, Kuroda M, et al. Genome and virulence determinants of high virulence community-acquired MRSA. Lancet 2002; 359: 1819–27PubMedCrossRef Baba T, Takeuchi F, Kuroda M, et al. Genome and virulence determinants of high virulence community-acquired MRSA. Lancet 2002; 359: 1819–27PubMedCrossRef
47.
Zurück zum Zitat Lina G, Piémont Y, Godail-Gamt F, et al. Involvement of Panton-Valentine leukocidin-producing Staphylococcus aureus in primary skin infections and pneumonia. Clin Infect Dis 1999; 29: 1128–32PubMedCrossRef Lina G, Piémont Y, Godail-Gamt F, et al. Involvement of Panton-Valentine leukocidin-producing Staphylococcus aureus in primary skin infections and pneumonia. Clin Infect Dis 1999; 29: 1128–32PubMedCrossRef
48.
Zurück zum Zitat Dufour P, Gillet Y, Bes M, et al. Community-acquired methicillin-resistant Staphylococcus aureus infections in France: emergence of a single clone that produces Panton-Valentine leukocidin. Clin Infect Dis 2002; 35: 819–24PubMedCrossRef Dufour P, Gillet Y, Bes M, et al. Community-acquired methicillin-resistant Staphylococcus aureus infections in France: emergence of a single clone that produces Panton-Valentine leukocidin. Clin Infect Dis 2002; 35: 819–24PubMedCrossRef
49.
Zurück zum Zitat Diep BA, Sensabaugh GF, Somboona NS, et al. Widespread skin and soft-tissue infections due to two methicillin-resistant Staphylococcus aureus strains harboring the genes for Panton-Valentine leucocidin. J Clin Microbiol 2004; 42: 2080–4PubMedCrossRef Diep BA, Sensabaugh GF, Somboona NS, et al. Widespread skin and soft-tissue infections due to two methicillin-resistant Staphylococcus aureus strains harboring the genes for Panton-Valentine leucocidin. J Clin Microbiol 2004; 42: 2080–4PubMedCrossRef
50.
Zurück zum Zitat Voyich JM, Otto M, Mathema B, et al. Is Panton-Valentine Leukocidin the major virulence determinant in community-associated methicillin-resistant Staphylococcus aureus disease? J Infect Dis 2006; 194: 1761–70PubMedCrossRef Voyich JM, Otto M, Mathema B, et al. Is Panton-Valentine Leukocidin the major virulence determinant in community-associated methicillin-resistant Staphylococcus aureus disease? J Infect Dis 2006; 194: 1761–70PubMedCrossRef
51.
Zurück zum Zitat Diep BA, Palazzolo-Balance AM, Tattevin P, et al. Contribution of Panton-Valentine leukocidin in communityassociated methicillin-resistant Staphylococcus aureus pathogenesis. PLoS One 2008; 3: e3198PubMedCrossRef Diep BA, Palazzolo-Balance AM, Tattevin P, et al. Contribution of Panton-Valentine leukocidin in communityassociated methicillin-resistant Staphylococcus aureus pathogenesis. PLoS One 2008; 3: e3198PubMedCrossRef
52.
Zurück zum Zitat Labandeira-Rey M, Couzon F, Boisset S, et al. Staphylococcus aureus Panton Valentine leukocidin causes necrotizing pneumonia. Science 2007; 315: 1130–3PubMedCrossRef Labandeira-Rey M, Couzon F, Boisset S, et al. Staphylococcus aureus Panton Valentine leukocidin causes necrotizing pneumonia. Science 2007; 315: 1130–3PubMedCrossRef
53.
Zurück zum Zitat Bubeck Wardenburg J, Bae T, Otto M, et al. Poring over the pores: α-hemolysin and Panton-Valentine leukocidin in Staphylococcus aureus pneumonia. Nat Med 2007; 13: 1405–6PubMedCrossRef Bubeck Wardenburg J, Bae T, Otto M, et al. Poring over the pores: α-hemolysin and Panton-Valentine leukocidin in Staphylococcus aureus pneumonia. Nat Med 2007; 13: 1405–6PubMedCrossRef
54.
Zurück zum Zitat Wardenburg JB, Palazzolo-Balance AM, Otto M, et al. Panton-Valentine is not a virulence determinant in murine models of community-associated methicillin-resistant Staphylococcus aureus disease. J Infect Dis 2008; 198: 1166–70CrossRef Wardenburg JB, Palazzolo-Balance AM, Otto M, et al. Panton-Valentine is not a virulence determinant in murine models of community-associated methicillin-resistant Staphylococcus aureus disease. J Infect Dis 2008; 198: 1166–70CrossRef
55.
Zurück zum Zitat Wang R, Braughton KR, Kretschmer D, et al. Identification of novel cytolytic peptides as key virulence determinants for community-associated MRSA. Nat Med 2007; 13: 1510–4PubMedCrossRef Wang R, Braughton KR, Kretschmer D, et al. Identification of novel cytolytic peptides as key virulence determinants for community-associated MRSA. Nat Med 2007; 13: 1510–4PubMedCrossRef
56.
Zurück zum Zitat Diep BA, Gill SR, Chang RF, et al. Complete genome sequence of USA300, an epidemic clone of community-acquired meticillin-resistant Staphylococcus aureus. Lancet 2006; 367: 731–9PubMedCrossRef Diep BA, Gill SR, Chang RF, et al. Complete genome sequence of USA300, an epidemic clone of community-acquired meticillin-resistant Staphylococcus aureus. Lancet 2006; 367: 731–9PubMedCrossRef
57.
Zurück zum Zitat Diep BA, Stone GC, Basuino L, et al. The arginine catabolic mobile element and staphylococcal chromosomal cassette mec linkage: convergence of virulence and resistance in the USA300 clone of methicillin-resistant Staphylococcus aureus. J Infect Dis 2008; 197: 1523–30PubMedCrossRef Diep BA, Stone GC, Basuino L, et al. The arginine catabolic mobile element and staphylococcal chromosomal cassette mec linkage: convergence of virulence and resistance in the USA300 clone of methicillin-resistant Staphylococcus aureus. J Infect Dis 2008; 197: 1523–30PubMedCrossRef
58.
Zurück zum Zitat Diep BA, Gill SR, Change RF, et al. Complete genome sequence of USA300, an epidemic clone of communityacquired meticillin-resistant Staphylococcus aureus. Lancet 2006; 367: 731–39PubMedCrossRef Diep BA, Gill SR, Change RF, et al. Complete genome sequence of USA300, an epidemic clone of communityacquired meticillin-resistant Staphylococcus aureus. Lancet 2006; 367: 731–39PubMedCrossRef
59.
Zurück zum Zitat Han LL, McDougal LK, Gorwitz RJ, et al. High frequencies of clindamycin and tetracycline resistance in methicillin-resistant Staphylococcus aureus pulsed-field type USA300 isolates collected at a Boston ambulatory health center. J Clin Microbiol 2007; 45: 1350–2PubMedCrossRef Han LL, McDougal LK, Gorwitz RJ, et al. High frequencies of clindamycin and tetracycline resistance in methicillin-resistant Staphylococcus aureus pulsed-field type USA300 isolates collected at a Boston ambulatory health center. J Clin Microbiol 2007; 45: 1350–2PubMedCrossRef
60.
Zurück zum Zitat Okuma K, Iwakawa K, Turnidge JD, et al. Dissemination of new methicillin-resistant Staphylococcus aureus clones in the community. J Clin Microbiol 2002; 40: 4289–94PubMedCrossRef Okuma K, Iwakawa K, Turnidge JD, et al. Dissemination of new methicillin-resistant Staphylococcus aureus clones in the community. J Clin Microbiol 2002; 40: 4289–94PubMedCrossRef
61.
Zurück zum Zitat Katayama Y, Ito T, Hiramatsu K. A new class of genetic element, staphylococcus cassette chromosome mec, encodes methicillin resistance in Staphylococcus aureus. Antimicrob Agents Chemother 2000; 44: 1549–55PubMedCrossRef Katayama Y, Ito T, Hiramatsu K. A new class of genetic element, staphylococcus cassette chromosome mec, encodes methicillin resistance in Staphylococcus aureus. Antimicrob Agents Chemother 2000; 44: 1549–55PubMedCrossRef
62.
Zurück zum Zitat Ito T, Katayama Y, Asada K, et al. Structural composition of three types of staphylococcal cassette chromosome mec integrated in the chromosome of methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2002; 46: 1147–52PubMedCrossRef Ito T, Katayama Y, Asada K, et al. Structural composition of three types of staphylococcal cassette chromosome mec integrated in the chromosome of methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2002; 46: 1147–52PubMedCrossRef
63.
Zurück zum Zitat Ma XX, Ito T, Tiensasitorn C, et al. Novel type of staphylococcal chromosome mec identified in communityacquired methicillin-resistant Staphylococcus aureus strains. Antimicrob Agents Chemother 2002; 46: 1147–52PubMedCrossRef Ma XX, Ito T, Tiensasitorn C, et al. Novel type of staphylococcal chromosome mec identified in communityacquired methicillin-resistant Staphylococcus aureus strains. Antimicrob Agents Chemother 2002; 46: 1147–52PubMedCrossRef
64.
Zurück zum Zitat Daum RS, Ito T, Hiramatsu K, et al. A novel methicillinresistance cassette in community-acquired methicillinresistant Staphylococcus aureus isolates of diverse genetic backgrounds. J Infect Dis 2002; 186: 1344–7PubMedCrossRef Daum RS, Ito T, Hiramatsu K, et al. A novel methicillinresistance cassette in community-acquired methicillinresistant Staphylococcus aureus isolates of diverse genetic backgrounds. J Infect Dis 2002; 186: 1344–7PubMedCrossRef
65.
Zurück zum Zitat Ito T, Ma XX, Takeuchi F, et al. Novel type V Staphylococcal cassette chromosome mec driven by a novel cassette chromosome recombinase, ccrC. Antimicrob Agents Chemother 2004; 48: 2637–51PubMedCrossRef Ito T, Ma XX, Takeuchi F, et al. Novel type V Staphylococcal cassette chromosome mec driven by a novel cassette chromosome recombinase, ccrC. Antimicrob Agents Chemother 2004; 48: 2637–51PubMedCrossRef
66.
Zurück zum Zitat Shore A, Rossney AS, Keane CT, et al. Seven novel variants of the staphylococcal chromosomal cassette mec in methicillin-resistant Staphylococcus aureus isolates from Ireland. Antimicrob Agents Chemother 2005; 49: 2070–83PubMedCrossRef Shore A, Rossney AS, Keane CT, et al. Seven novel variants of the staphylococcal chromosomal cassette mec in methicillin-resistant Staphylococcus aureus isolates from Ireland. Antimicrob Agents Chemother 2005; 49: 2070–83PubMedCrossRef
67.
Zurück zum Zitat King MD, Humphrey BH, Want YF, et al. Emergence of community-acquired methicillin-resistant Staphylococcus aureus USA 300 clone as the predominant cause of skin and soft-tissue infections. Ann Intern Med 2006; 144: 309–17PubMed King MD, Humphrey BH, Want YF, et al. Emergence of community-acquired methicillin-resistant Staphylococcus aureus USA 300 clone as the predominant cause of skin and soft-tissue infections. Ann Intern Med 2006; 144: 309–17PubMed
68.
Zurück zum Zitat Miller LG, Quan C, Shay A, et al. A prospective investigation of outcomes after hospital discharge for endemic, community-acquired methicillin-resistant and -susceptible Staphylococcus aureus skin infection. Clin Infect Dis 2007; 44: 483–92PubMedCrossRef Miller LG, Quan C, Shay A, et al. A prospective investigation of outcomes after hospital discharge for endemic, community-acquired methicillin-resistant and -susceptible Staphylococcus aureus skin infection. Clin Infect Dis 2007; 44: 483–92PubMedCrossRef
69.
Zurück zum Zitat Graber CJ, Jacobson MA, Perdreau-Remington F, et al. Recurrence of skin and soft tissue infection caused by methicillin-resistant Staphylococcus aureus in a HIV primary care clinic. J Acquired Immune Defic Syndr 2008; 49: 231–3CrossRef Graber CJ, Jacobson MA, Perdreau-Remington F, et al. Recurrence of skin and soft tissue infection caused by methicillin-resistant Staphylococcus aureus in a HIV primary care clinic. J Acquired Immune Defic Syndr 2008; 49: 231–3CrossRef
70.
Zurück zum Zitat Miller LG, Perdreau-Remington F, Rieg G, et al. Necrotizing fasciitis caused by community-associated methicillin-resistant Staphylococcus aureus in Los Angeles. N Engl J Med 2005; 352: 1445–53PubMedCrossRef Miller LG, Perdreau-Remington F, Rieg G, et al. Necrotizing fasciitis caused by community-associated methicillin-resistant Staphylococcus aureus in Los Angeles. N Engl J Med 2005; 352: 1445–53PubMedCrossRef
71.
Zurück zum Zitat Fowler A, Mackay A. Community-acquired methicillinresistant Staphylococcus aureus pyomyositis in an intravenous drug user. J Med Microbiol 2006; 55: 123–5PubMedCrossRef Fowler A, Mackay A. Community-acquired methicillinresistant Staphylococcus aureus pyomyositis in an intravenous drug user. J Med Microbiol 2006; 55: 123–5PubMedCrossRef
72.
Zurück zum Zitat Dehority W, Wang E, Vernon PS, et al. Communityassociated methicillin-resistant Staphylococcus aureus necrotizing fasciitis in a neonate. Pediatr Infect Dis J 2006; 25: 1080–1PubMedCrossRef Dehority W, Wang E, Vernon PS, et al. Communityassociated methicillin-resistant Staphylococcus aureus necrotizing fasciitis in a neonate. Pediatr Infect Dis J 2006; 25: 1080–1PubMedCrossRef
73.
Zurück zum Zitat Pannaraj PS, Hulten KG, Gonzalez BE, et al. Infective pyomyositis and myositis in children in the era of community-acquired, methicillin-resistant Staphylococcus aureus infection. Clin Infect Dis 2006; 43: 953–60PubMedCrossRef Pannaraj PS, Hulten KG, Gonzalez BE, et al. Infective pyomyositis and myositis in children in the era of community-acquired, methicillin-resistant Staphylococcus aureus infection. Clin Infect Dis 2006; 43: 953–60PubMedCrossRef
74.
Zurück zum Zitat Sokolov KM, Kreye E, Miller LG, et al. Postpartum iliopsoas pyomyositis due to community-acquired methicillin-resistant Staphylococcus aureus. Obstet Gynel 2007; 110: 535–8CrossRef Sokolov KM, Kreye E, Miller LG, et al. Postpartum iliopsoas pyomyositis due to community-acquired methicillin-resistant Staphylococcus aureus. Obstet Gynel 2007; 110: 535–8CrossRef
75.
Zurück zum Zitat Shedek BK, Nilles EJ. Community-associated methicillinresistant Staphylococcus aureus pyomyositis complicated by compartment syndrome in an immunocompetent young woman. Am J Emerg Med 2008; 26: 737.e3-4PubMedCrossRef Shedek BK, Nilles EJ. Community-associated methicillinresistant Staphylococcus aureus pyomyositis complicated by compartment syndrome in an immunocompetent young woman. Am J Emerg Med 2008; 26: 737.e3-4PubMedCrossRef
76.
Zurück zum Zitat Burton MJ, Shah P, Swiatlo E. Community-acquired methicillin-resistant Staphylococcus aureus as a cause of Fournier’s gangrene. Am J Med Sci 2008; 335: 327–8PubMedCrossRef Burton MJ, Shah P, Swiatlo E. Community-acquired methicillin-resistant Staphylococcus aureus as a cause of Fournier’s gangrene. Am J Med Sci 2008; 335: 327–8PubMedCrossRef
77.
Zurück zum Zitat Gillet Y, Issartel B, Vanhems P, et al. Association between Staphylococcus aureus strains carrying gene for Panton-Valentine leukocidin and highly lethal necrotizing pneumonia in young immunocompetent patients. Lancet 2002; 359: 753–9PubMedCrossRef Gillet Y, Issartel B, Vanhems P, et al. Association between Staphylococcus aureus strains carrying gene for Panton-Valentine leukocidin and highly lethal necrotizing pneumonia in young immunocompetent patients. Lancet 2002; 359: 753–9PubMedCrossRef
78.
Zurück zum Zitat Francis JS, Doherty MC, Lopatin U, et al. Severe community-onset pneumonia in healthy adults caused by methicillin-resistant Staphylococcus aureus carrying the Panton-Valentine leukocidin genes. Clin Infect Dis 2005; 40: 100–7PubMedCrossRef Francis JS, Doherty MC, Lopatin U, et al. Severe community-onset pneumonia in healthy adults caused by methicillin-resistant Staphylococcus aureus carrying the Panton-Valentine leukocidin genes. Clin Infect Dis 2005; 40: 100–7PubMedCrossRef
79.
Zurück zum Zitat Gonzalez BE, Hulten KG, Dishop MK, et al. Pulmonary manifestations in children with invasive communityacquired Staphylococcus aureus infection. Clin Infect Dis 2005; 41: 583–90PubMedCrossRef Gonzalez BE, Hulten KG, Dishop MK, et al. Pulmonary manifestations in children with invasive communityacquired Staphylococcus aureus infection. Clin Infect Dis 2005; 41: 583–90PubMedCrossRef
80.
Zurück zum Zitat Hageman JC, Uyeki TM, Francis JS, et al. Severe community-acquired pneumonia due to Staphylococcus aureus, 2003–04 influenza season. Emerg Infect Dis 2006; 12: 894–9PubMedCrossRef Hageman JC, Uyeki TM, Francis JS, et al. Severe community-acquired pneumonia due to Staphylococcus aureus, 2003–04 influenza season. Emerg Infect Dis 2006; 12: 894–9PubMedCrossRef
81.
Zurück zum Zitat Centers for Disease Control and Prevention. Severe methicillin-resistant Staphylococcus aureus communityacquired pneumonia associated with influenza — Louisiana and Georgia, December 2006–January 2007. MMWR Morb Mortal Wkly Rep 2007; 56: 325–9 Centers for Disease Control and Prevention. Severe methicillin-resistant Staphylococcus aureus communityacquired pneumonia associated with influenza — Louisiana and Georgia, December 2006–January 2007. MMWR Morb Mortal Wkly Rep 2007; 56: 325–9
82.
Zurück zum Zitat Martínez-Aguilar G, Hammerman WA, Mason EO, et al. Clindamycin treatment of invasive infections caused by community-acquired methicillin-resistant and methicillinsusceptible Staphylococcus aureus in children. Pediatr Infect Dis J 2003; 22: 593–8PubMed Martínez-Aguilar G, Hammerman WA, Mason EO, et al. Clindamycin treatment of invasive infections caused by community-acquired methicillin-resistant and methicillinsusceptible Staphylococcus aureus in children. Pediatr Infect Dis J 2003; 22: 593–8PubMed
83.
Zurück zum Zitat Arnold SR, Elias D, Buckingham SC, et al. Changing patterns of acute hematogenous osteomyelitis and septic arthritis. J Pediatr Orthop 2006; 26: 703–8PubMedCrossRef Arnold SR, Elias D, Buckingham SC, et al. Changing patterns of acute hematogenous osteomyelitis and septic arthritis. J Pediatr Orthop 2006; 26: 703–8PubMedCrossRef
84.
Zurück zum Zitat Gonzalez BE, Teruya J, Mahoney DH, et al. Venous thrombosis associated with staphylococcal osteomyelitis in children. Pediatrics 2006; 117: 1673–9PubMedCrossRef Gonzalez BE, Teruya J, Mahoney DH, et al. Venous thrombosis associated with staphylococcal osteomyelitis in children. Pediatrics 2006; 117: 1673–9PubMedCrossRef
85.
Zurück zum Zitat Gillet Y, Dohin B, Dumitrescu O, et al. Osteoarticular infections with Staphylococcus aureus secreting Panton-Valentine leucocidin. Arch Pediatr 2007; 14: S102–7PubMedCrossRef Gillet Y, Dohin B, Dumitrescu O, et al. Osteoarticular infections with Staphylococcus aureus secreting Panton-Valentine leucocidin. Arch Pediatr 2007; 14: S102–7PubMedCrossRef
86.
Zurück zum Zitat Crum NF. The emergence of severe, community-acquired methicillin-resistant Staphylococcus aureus infections. Scand J Infect Dis 2005; 37: 651–6PubMedCrossRef Crum NF. The emergence of severe, community-acquired methicillin-resistant Staphylococcus aureus infections. Scand J Infect Dis 2005; 37: 651–6PubMedCrossRef
87.
Zurück zum Zitat Seybold U, Talati NJ, Shah M, et al. Hematogenous osteomyelitis mimicking osteosarcoma due to community-associated methicillin-resistant Staphylococcus aureus. Infection 2007; 35: 190–3PubMedCrossRef Seybold U, Talati NJ, Shah M, et al. Hematogenous osteomyelitis mimicking osteosarcoma due to community-associated methicillin-resistant Staphylococcus aureus. Infection 2007; 35: 190–3PubMedCrossRef
88.
Zurück zum Zitat Nourse C, Starr M, Munckhof W. Community-acquired methicillin-resistant Staphylococcus aureus causes severe disseminated infection and deep venous thrombosis in children: literature review and recommendations for management. J Paediatr Child Health 2007; 43: 656–61PubMedCrossRef Nourse C, Starr M, Munckhof W. Community-acquired methicillin-resistant Staphylococcus aureus causes severe disseminated infection and deep venous thrombosis in children: literature review and recommendations for management. J Paediatr Child Health 2007; 43: 656–61PubMedCrossRef
89.
Zurück zum Zitat Bahrain M, Vasiliades M, Wolff M, et al. Five cases of bacterial endocarditis after furunculosis and the ongoing saga of community-acquired methicillin-resistant Staphylococcus aureus infections. Scand J Infect Dis 2006; 38: 702–7PubMedCrossRef Bahrain M, Vasiliades M, Wolff M, et al. Five cases of bacterial endocarditis after furunculosis and the ongoing saga of community-acquired methicillin-resistant Staphylococcus aureus infections. Scand J Infect Dis 2006; 38: 702–7PubMedCrossRef
90.
Zurück zum Zitat Haque NZ, Davis SL, Manierski CL, et al. Infective endocarditis caused by USA300 methicillin-resistant Staphylococcus aureus (MRSA). Int J Antimicrob Agents 2007; 30: 72–7PubMedCrossRef Haque NZ, Davis SL, Manierski CL, et al. Infective endocarditis caused by USA300 methicillin-resistant Staphylococcus aureus (MRSA). Int J Antimicrob Agents 2007; 30: 72–7PubMedCrossRef
91.
Zurück zum Zitat Gonzalez BE, Martinez-Aguilar G, Hulten KG, et al. Severe staphylococcal sepsis in adolescents in the era of community-acquired methicillin-resistant Staphylococcus aureus. Pediatrics 2005; 115: 642–8PubMedCrossRef Gonzalez BE, Martinez-Aguilar G, Hulten KG, et al. Severe staphylococcal sepsis in adolescents in the era of community-acquired methicillin-resistant Staphylococcus aureus. Pediatrics 2005; 115: 642–8PubMedCrossRef
92.
Zurück zum Zitat Kravitz GR, Dries DJ, Peterson ML, et al. Purpura fulminans due to Staphylococcus aureus. Clin Infect Dis 2005; 40: 941–7PubMedCrossRef Kravitz GR, Dries DJ, Peterson ML, et al. Purpura fulminans due to Staphylococcus aureus. Clin Infect Dis 2005; 40: 941–7PubMedCrossRef
93.
Zurück zum Zitat Adem PV, Montgomery CP, Husain AN, et al. Staphylococcus aureus sepsis and the Waterhouse-Friderichsen syndrome in children. N Engl J Med 2005; 353: 1245–51PubMedCrossRef Adem PV, Montgomery CP, Husain AN, et al. Staphylococcus aureus sepsis and the Waterhouse-Friderichsen syndrome in children. N Engl J Med 2005; 353: 1245–51PubMedCrossRef
94.
Zurück zum Zitat Valentine P, Parisi G, Monaco M, et al. An uncommon presentation for a severe invasive infection due to methicillinresistant Staphylococcus aureus clone USA300 in Italy: a case report. Ann Clin Microbiol Antimicrob 2008; 7: 11CrossRef Valentine P, Parisi G, Monaco M, et al. An uncommon presentation for a severe invasive infection due to methicillinresistant Staphylococcus aureus clone USA300 in Italy: a case report. Ann Clin Microbiol Antimicrob 2008; 7: 11CrossRef
95.
Zurück zum Zitat Munckhof WJ, Krishnan A, Kruger P, et al. Cavernous sinus thrombosis and meningitis from communityacquired methicillin-resistant Staphylococcus aureus infection. Intern Med J 2008; 38: 283–7PubMedCrossRef Munckhof WJ, Krishnan A, Kruger P, et al. Cavernous sinus thrombosis and meningitis from communityacquired methicillin-resistant Staphylococcus aureus infection. Intern Med J 2008; 38: 283–7PubMedCrossRef
96.
Zurück zum Zitat Saiman L, O’Keefe M, Graham PL, et al. Hospital transmission of community-acquired methicillin-resistant Staphylococcus aureus among postpartum women. Clin Infect Dis 2003; 37: 1313–9PubMedCrossRef Saiman L, O’Keefe M, Graham PL, et al. Hospital transmission of community-acquired methicillin-resistant Staphylococcus aureus among postpartum women. Clin Infect Dis 2003; 37: 1313–9PubMedCrossRef
97.
Zurück zum Zitat Stafford I, Hernandez J, Laibl V, et al. Communityacquired methicillin-resistant Staphylococcus aureus among patients with puerperal mastitis requiring hospitalization. Obstet Gynecol 2008; 112: 533–7PubMedCrossRef Stafford I, Hernandez J, Laibl V, et al. Communityacquired methicillin-resistant Staphylococcus aureus among patients with puerperal mastitis requiring hospitalization. Obstet Gynecol 2008; 112: 533–7PubMedCrossRef
98.
Zurück zum Zitat Rutar T, Chamber HF, Crawford JB, et al. Ophthalmic manifestations of infections caused by the USA300 clone of community-associated methicillin-resistant Staphylococcus aureus. Ophthalmology 2006; 113: 1455–62PubMedCrossRef Rutar T, Chamber HF, Crawford JB, et al. Ophthalmic manifestations of infections caused by the USA300 clone of community-associated methicillin-resistant Staphylococcus aureus. Ophthalmology 2006; 113: 1455–62PubMedCrossRef
99.
Zurück zum Zitat Healy CM, Hulten KG, Palazzi DL, et al. Emergence of new strains of methicillin-resistant Staphylococcus aureus in a neonatal intensive care unit. Clin Infect Dis 2004; 39: 1460–6PubMedCrossRef Healy CM, Hulten KG, Palazzi DL, et al. Emergence of new strains of methicillin-resistant Staphylococcus aureus in a neonatal intensive care unit. Clin Infect Dis 2004; 39: 1460–6PubMedCrossRef
100.
Zurück zum Zitat De A Trindade P, Pacheco RL, Costa SF, et al. Prevalence of SCCmec Type IV in nosocomial bloodstream isolates of methicillin-resistant Staphylococcus aureus. J Clin Microbiol 2005; 43: 3435–7CrossRef De A Trindade P, Pacheco RL, Costa SF, et al. Prevalence of SCCmec Type IV in nosocomial bloodstream isolates of methicillin-resistant Staphylococcus aureus. J Clin Microbiol 2005; 43: 3435–7CrossRef
101.
Zurück zum Zitat Regev-Yochay G, Rubinstein E, Barzilai A, et al. Methicillin-resistant Staphylococcus aureus in neonatal intensive care unit. Emerg Infect Dis 2005; 11: 453–56PubMedCrossRef Regev-Yochay G, Rubinstein E, Barzilai A, et al. Methicillin-resistant Staphylococcus aureus in neonatal intensive care unit. Emerg Infect Dis 2005; 11: 453–56PubMedCrossRef
102.
Zurück zum Zitat Seybold U, Kourbatova EV, Johnson JG, et al. Emergence of community-associated methicillin-resistant Staphylococcus aureus USA300 genotype as a major cause of health-care-associated blood stream infections. Clin Infect Dis 2006; 42: 647–56PubMedCrossRef Seybold U, Kourbatova EV, Johnson JG, et al. Emergence of community-associated methicillin-resistant Staphylococcus aureus USA300 genotype as a major cause of health-care-associated blood stream infections. Clin Infect Dis 2006; 42: 647–56PubMedCrossRef
103.
Zurück zum Zitat Davis SL, Rybak MJ, Amjad M, et al. Characteristics of patients with healthcare-associated infection due to SCCmec type IV methicillin-resistant Staphylococcus aureus. Infect Control Hosp Epidemiol 2006; 27: 1025–31PubMedCrossRef Davis SL, Rybak MJ, Amjad M, et al. Characteristics of patients with healthcare-associated infection due to SCCmec type IV methicillin-resistant Staphylococcus aureus. Infect Control Hosp Epidemiol 2006; 27: 1025–31PubMedCrossRef
104.
Zurück zum Zitat Laplante KL, Rybak MJ, Amjad M, et al. Antimicrobial susceptibility and staphylococcal chromosomal cassette mec type in community- and hospital-associated methicillin-resistant Staphylococcus aureus. Pharmacotherapy 2007; 27: 3–10PubMedCrossRef Laplante KL, Rybak MJ, Amjad M, et al. Antimicrobial susceptibility and staphylococcal chromosomal cassette mec type in community- and hospital-associated methicillin-resistant Staphylococcus aureus. Pharmacotherapy 2007; 27: 3–10PubMedCrossRef
105.
Zurück zum Zitat Benoit SR, Estivariz C, Mogdasy C, et al. Community strains of methicillin-resistant Staphylococcus aureus as potential cause of healthcare-associated infections, Uruguay, 2002–2004. Emerg Infect Dis 2008: 14: 1216–23PubMedCrossRef Benoit SR, Estivariz C, Mogdasy C, et al. Community strains of methicillin-resistant Staphylococcus aureus as potential cause of healthcare-associated infections, Uruguay, 2002–2004. Emerg Infect Dis 2008: 14: 1216–23PubMedCrossRef
106.
Zurück zum Zitat Kourbatova EV, Halvosa JS, King MD, et al. Emergence of community-associated methicillin-resistant Staphylococcus aureus USA 300 clone as a cause of health careassociated infections among patients with prosthetic joint infections. Am J Infect Control 2005; 33: 385–91PubMedCrossRef Kourbatova EV, Halvosa JS, King MD, et al. Emergence of community-associated methicillin-resistant Staphylococcus aureus USA 300 clone as a cause of health careassociated infections among patients with prosthetic joint infections. Am J Infect Control 2005; 33: 385–91PubMedCrossRef
107.
Zurück zum Zitat Patel M, Kumar RA, Stamm A, et al. USA300 genotype community-associated methicillin-resistant Staphylococcus aureus as a cause of surgical-site infections. J Clin Microbiol 2007; 45: 3431–3PubMedCrossRef Patel M, Kumar RA, Stamm A, et al. USA300 genotype community-associated methicillin-resistant Staphylococcus aureus as a cause of surgical-site infections. J Clin Microbiol 2007; 45: 3431–3PubMedCrossRef
108.
Zurück zum Zitat Popovich KJ, Weinstein RA, Hota B. Are communityassociated methicillin-resistant Staphylococcus aureus (MRSA) strains replacing traditional nosocomial MRSA strains? Clin Infect Dis 2008; 46: 787–94PubMedCrossRef Popovich KJ, Weinstein RA, Hota B. Are communityassociated methicillin-resistant Staphylococcus aureus (MRSA) strains replacing traditional nosocomial MRSA strains? Clin Infect Dis 2008; 46: 787–94PubMedCrossRef
109.
Zurück zum Zitat Patel M, Waites KB, Hoesley CJ, et al. Emergence of USA300 MRSA in a tertiary medical centre: implications for epidemiologic studies. J Hosp Infect 2008; 68: 208–13PubMedCrossRef Patel M, Waites KB, Hoesley CJ, et al. Emergence of USA300 MRSA in a tertiary medical centre: implications for epidemiologic studies. J Hosp Infect 2008; 68: 208–13PubMedCrossRef
110.
Zurück zum Zitat Liu C, Graber CJ, Karr M, et al. A population-based study of the incidence and molecular epidemiology of methicillin-resistant Staphylococcus aureus disease in San Francisco, 2004–2005. Clin Infect Dis 2008; 46: 1637–46PubMedCrossRef Liu C, Graber CJ, Karr M, et al. A population-based study of the incidence and molecular epidemiology of methicillin-resistant Staphylococcus aureus disease in San Francisco, 2004–2005. Clin Infect Dis 2008; 46: 1637–46PubMedCrossRef
111.
Zurück zum Zitat Noel GJ, Bush K, Bagchi P, et al. A randomized, double-blind trial comparing ceftobiprole medocaril with vancomycin plus ceftazidime for the treatment of patients with complicated skin and skin-structure infections. Clin Infect Dis 2008; 46: 647–55PubMedCrossRef Noel GJ, Bush K, Bagchi P, et al. A randomized, double-blind trial comparing ceftobiprole medocaril with vancomycin plus ceftazidime for the treatment of patients with complicated skin and skin-structure infections. Clin Infect Dis 2008; 46: 647–55PubMedCrossRef
112.
Zurück zum Zitat Cleocin (clindamycin) for injection [package insert]. Bedford (OH): Ben Venue Laboratories, 2004 Cleocin (clindamycin) for injection [package insert]. Bedford (OH): Ben Venue Laboratories, 2004
113.
Zurück zum Zitat Cubicin (daptomycin) for injection [package insert]. Lexington (MA): Cubist Pharmaceuticals, 2007 Cubicin (daptomycin) for injection [package insert]. Lexington (MA): Cubist Pharmaceuticals, 2007
114.
Zurück zum Zitat Vibramycin (doxycycline) [package insert]. New York: Pfizer Pharmaceuticals, 2007 Vibramycin (doxycycline) [package insert]. New York: Pfizer Pharmaceuticals, 2007
115.
Zurück zum Zitat Zyvox (linezolid) [package insert]. New York: Pharmacia & Upjohn, Division of Pfizer, 2007 Zyvox (linezolid) [package insert]. New York: Pharmacia & Upjohn, Division of Pfizer, 2007
116.
Zurück zum Zitat Synercid (quinupristin and dalfopristin) for injection [package insert]. Bristol (TN): Monarch Pharmaceuticals, 2003 Synercid (quinupristin and dalfopristin) for injection [package insert]. Bristol (TN): Monarch Pharmaceuticals, 2003
117.
Zurück zum Zitat Tygacil (tigecycline) for injection [package insert]. Philadelphia (PA): Wyeth Pharmaceuticals, 2006 Tygacil (tigecycline) for injection [package insert]. Philadelphia (PA): Wyeth Pharmaceuticals, 2006
118.
Zurück zum Zitat Bactrim (sulfamethoxazole and trimethoprim tablets) [package insert]. Nutley (NJ): Roche Pharmaceuticals, 2002 Bactrim (sulfamethoxazole and trimethoprim tablets) [package insert]. Nutley (NJ): Roche Pharmaceuticals, 2002
119.
Zurück zum Zitat Rybak M, Lomaestro B, Rotschafer JC, et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health-Syst Pharm 2009; 66: 82–98PubMedCrossRef Rybak M, Lomaestro B, Rotschafer JC, et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health-Syst Pharm 2009; 66: 82–98PubMedCrossRef
120.
Zurück zum Zitat Ruhe JJ, Monson T, Bradsher RW, et al. Use of long-acting tetracyclines for methicillin-resistant Staphylococcus aureus infections: case series and review of the literature. Clin Infect Dis 2005; 40: 1429–34PubMedCrossRef Ruhe JJ, Monson T, Bradsher RW, et al. Use of long-acting tetracyclines for methicillin-resistant Staphylococcus aureus infections: case series and review of the literature. Clin Infect Dis 2005; 40: 1429–34PubMedCrossRef
121.
Zurück zum Zitat Clinical and Laboratory Standards Institute/NCCLS. Methods for antimicrobial susceptibility testing for bacteria that grow aerobically. CLSI/NCCLS M100-S 14. Wayne (PA): National Committee for Clinical Laboratory Standards, 2004 Clinical and Laboratory Standards Institute/NCCLS. Methods for antimicrobial susceptibility testing for bacteria that grow aerobically. CLSI/NCCLS M100-S 14. Wayne (PA): National Committee for Clinical Laboratory Standards, 2004
122.
Zurück zum Zitat Chavez-Bueno S, Bozdogan B, Katz K, et al. Inducible clindamycin resistance and molecular epidemiologic trends of pediatric community-associated methicillinresistant Staphylococcus aureus in Dallas, Texas. Antimicrob Agents Chemother 2005; 49: 2283–88PubMedCrossRef Chavez-Bueno S, Bozdogan B, Katz K, et al. Inducible clindamycin resistance and molecular epidemiologic trends of pediatric community-associated methicillinresistant Staphylococcus aureus in Dallas, Texas. Antimicrob Agents Chemother 2005; 49: 2283–88PubMedCrossRef
123.
Zurück zum Zitat McGehee RF, Barrett FF, Finland M. Resistance of Staphylococcus aureus to lincomycin, clindamycin, and erythromycin. Antimicrob Agents Chemother 1968; 8: 392–7 McGehee RF, Barrett FF, Finland M. Resistance of Staphylococcus aureus to lincomycin, clindamycin, and erythromycin. Antimicrob Agents Chemother 1968; 8: 392–7
124.
Zurück zum Zitat Rao GG. Should clindamycin be used in treatment of patients with infections caused by erythromycin-resistant staphylococci? [letter]. J Antimicrob Chemother 2000; 45: 715PubMedCrossRef Rao GG. Should clindamycin be used in treatment of patients with infections caused by erythromycin-resistant staphylococci? [letter]. J Antimicrob Chemother 2000; 45: 715PubMedCrossRef
125.
Zurück zum Zitat Drinkovic D, Fuller ER, Shore KP, et al. Clindamycin treatment of Staphylococcus aureus expressing inducible clindamycin resistance. J Antimicrob Chemother 2001; 48: 315–6PubMedCrossRef Drinkovic D, Fuller ER, Shore KP, et al. Clindamycin treatment of Staphylococcus aureus expressing inducible clindamycin resistance. J Antimicrob Chemother 2001; 48: 315–6PubMedCrossRef
126.
Zurück zum Zitat Frank AL, Marcinak JF, Mahgat PD, et al. Clindamycin treatment of methicillin-resistant Staphylococcus aureus infections in children. Pediatr Infect Dis J 2002; 21: 530–34PubMedCrossRef Frank AL, Marcinak JF, Mahgat PD, et al. Clindamycin treatment of methicillin-resistant Staphylococcus aureus infections in children. Pediatr Infect Dis J 2002; 21: 530–34PubMedCrossRef
127.
Zurück zum Zitat Levin TP, Suh B, Axelrod P, et al. Potential clindamycin resistance in clindamycin-susceptible, erythromycinresistant Staphylococcus aureus: report of a clinical failure. Antimicrob Agents Chemother 2005; 49: 1222–4PubMedCrossRef Levin TP, Suh B, Axelrod P, et al. Potential clindamycin resistance in clindamycin-susceptible, erythromycinresistant Staphylococcus aureus: report of a clinical failure. Antimicrob Agents Chemother 2005; 49: 1222–4PubMedCrossRef
128.
Zurück zum Zitat Siberry GK, Tekle T, Carroll K, et al. Failure of clindamycin treatment of methicillin-resistant Staphylococcus aureus expressing inducible clindamycin resistance in vitro. Clin Infect Dis 2003; 37: 1257–60PubMedCrossRef Siberry GK, Tekle T, Carroll K, et al. Failure of clindamycin treatment of methicillin-resistant Staphylococcus aureus expressing inducible clindamycin resistance in vitro. Clin Infect Dis 2003; 37: 1257–60PubMedCrossRef
129.
Zurück zum Zitat LaPlante KL, Leonard SN, Andes DR, et al. Activities of clindamycin, daptomycin, doxycycline, linezolid, trimethoprim-sulfamethoxazole, and vancomycin against community-associated methicillin-resistant Staphylococcus aureus with inducible clindamycin resistance in murine thigh infection and in vitro pharmocodynamic models. Antimicrob Agents Chemother 2008; 52: 2156–62PubMedCrossRef LaPlante KL, Leonard SN, Andes DR, et al. Activities of clindamycin, daptomycin, doxycycline, linezolid, trimethoprim-sulfamethoxazole, and vancomycin against community-associated methicillin-resistant Staphylococcus aureus with inducible clindamycin resistance in murine thigh infection and in vitro pharmocodynamic models. Antimicrob Agents Chemother 2008; 52: 2156–62PubMedCrossRef
130.
Zurück zum Zitat Markowitz N, Quinn EL, Saravolatz LD. Trimethoprimsulfamethoxazole compared with vancomycin for the treatment of Staphylococcus aureus infection. Ann Intern Med 1992; 117: 390–8PubMed Markowitz N, Quinn EL, Saravolatz LD. Trimethoprimsulfamethoxazole compared with vancomycin for the treatment of Staphylococcus aureus infection. Ann Intern Med 1992; 117: 390–8PubMed
131.
Zurück zum Zitat Kaka AS, Rueda AM, Shelburn 3rd SA, et al. Bactericidal activity of oral agents against methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother 2006; 58: 680–3PubMedCrossRef Kaka AS, Rueda AM, Shelburn 3rd SA, et al. Bactericidal activity of oral agents against methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother 2006; 58: 680–3PubMedCrossRef
132.
Zurück zum Zitat Berg T, Firth N, Apisiridej S, et al. Complete nucleotide sequence of pSK41: evolution of staphylococcal conjugative plasmids. J Bacteriol 1998; 180: 4350–9PubMed Berg T, Firth N, Apisiridej S, et al. Complete nucleotide sequence of pSK41: evolution of staphylococcal conjugative plasmids. J Bacteriol 1998; 180: 4350–9PubMed
133.
Zurück zum Zitat Stokes A, Lacey RW. Effect of thymidine on activity of trimethoprim and sulphamethoxazole. J Clin Pathol 1978; 31: 165–71PubMedCrossRef Stokes A, Lacey RW. Effect of thymidine on activity of trimethoprim and sulphamethoxazole. J Clin Pathol 1978; 31: 165–71PubMedCrossRef
134.
Zurück zum Zitat Hamilton-Miller JM. Reversal of activity of trimethoprim against Gram-positive cocci by thymidine, thymine, and ‘folates‘. J Antimicrob Chemother 1988; 22: 35–9PubMedCrossRef Hamilton-Miller JM. Reversal of activity of trimethoprim against Gram-positive cocci by thymidine, thymine, and ‘folates‘. J Antimicrob Chemother 1988; 22: 35–9PubMedCrossRef
135.
Zurück zum Zitat Mendes RE, Sader HS, Deshpande L, et al. Antimicrobial activity of tigecycline against community-acquired methicillin-resistant Staphylococcus aureus isolates recovered from North American medical centers. Diagn Microbiol Infect Dis 2008; 60: 433–6PubMedCrossRef Mendes RE, Sader HS, Deshpande L, et al. Antimicrobial activity of tigecycline against community-acquired methicillin-resistant Staphylococcus aureus isolates recovered from North American medical centers. Diagn Microbiol Infect Dis 2008; 60: 433–6PubMedCrossRef
136.
Zurück zum Zitat Szumowski JD, Cohen DE, Kanaya F, et al. Treatment and outcomes of infections by methicillin-resistant Staphylococcus aureus at an ambulatory clinic. Antimicrob Agents Chemother 2007; 51: 423–28PubMedCrossRef Szumowski JD, Cohen DE, Kanaya F, et al. Treatment and outcomes of infections by methicillin-resistant Staphylococcus aureus at an ambulatory clinic. Antimicrob Agents Chemother 2007; 51: 423–28PubMedCrossRef
137.
Zurück zum Zitat Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. CLSI approved standard M100-S 16. Wayne (PA): Clinical and Laboratory Standards Institute, 2006 Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. CLSI approved standard M100-S 16. Wayne (PA): Clinical and Laboratory Standards Institute, 2006
138.
Zurück zum Zitat Jones RN. Microbiologic features of vancomycin in the 21st century: minimum inhibitory concentration creep, bactericidal/static activity, and applied breakpoints to predict clinical outcomes or detect resistant strains. Clin Infect Dis 2006; 42 Suppl. 1: S13–24PubMedCrossRef Jones RN. Microbiologic features of vancomycin in the 21st century: minimum inhibitory concentration creep, bactericidal/static activity, and applied breakpoints to predict clinical outcomes or detect resistant strains. Clin Infect Dis 2006; 42 Suppl. 1: S13–24PubMedCrossRef
139.
Zurück zum Zitat Wang G, Hindler JF, Ward KW, et al. Increased vancomycin MICs for Staphylococcus aureus clinical isolates from a university hospital during a 5-year period. J Clin Microbiol 2006; 44: 3883–6PubMedCrossRef Wang G, Hindler JF, Ward KW, et al. Increased vancomycin MICs for Staphylococcus aureus clinical isolates from a university hospital during a 5-year period. J Clin Microbiol 2006; 44: 3883–6PubMedCrossRef
140.
Zurück zum Zitat Steinkraus G, White R, Friedrich L. Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001–2005. J Antimicrob Chemother 2007; 60: 788–94PubMedCrossRef Steinkraus G, White R, Friedrich L. Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001–2005. J Antimicrob Chemother 2007; 60: 788–94PubMedCrossRef
141.
Zurück zum Zitat Rybak MJ, Leonard SN, Rossi KL, et al. Characterization of vancomycin-heteroresistant Staphylococcus aureus from the metropolitan area of Detroit, Michigan, over a 22-year period (1986–2007). J Clin Microbiol 2008; 46: 2950–4PubMedCrossRef Rybak MJ, Leonard SN, Rossi KL, et al. Characterization of vancomycin-heteroresistant Staphylococcus aureus from the metropolitan area of Detroit, Michigan, over a 22-year period (1986–2007). J Clin Microbiol 2008; 46: 2950–4PubMedCrossRef
142.
Zurück zum Zitat Moise-Broder PA, Sakoulas G, Eliopoulas J, et al. Accessory gene regulator group II polymorphism in methicillinresistant Staphylococcus aureus is predictive of failure of vancomycin therapy. Clin Infect Dis 2004; 38: 1700–5PubMedCrossRef Moise-Broder PA, Sakoulas G, Eliopoulas J, et al. Accessory gene regulator group II polymorphism in methicillinresistant Staphylococcus aureus is predictive of failure of vancomycin therapy. Clin Infect Dis 2004; 38: 1700–5PubMedCrossRef
143.
Zurück zum Zitat Sakoulas G, Moise-Broder PA, Schentag J, et al. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J Clin Microbiol 2004; 42: 2398–402PubMedCrossRef Sakoulas G, Moise-Broder PA, Schentag J, et al. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J Clin Microbiol 2004; 42: 2398–402PubMedCrossRef
144.
Zurück zum Zitat Soriano A, Marco F, Martinez JA, et al. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis 2008; 46: 193–200PubMedCrossRef Soriano A, Marco F, Martinez JA, et al. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis 2008; 46: 193–200PubMedCrossRef
145.
Zurück zum Zitat Lodise TP, Graves J, Evans A, et al. Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin. Antimicrob Agents Chemother 2008; 52: 3315–20PubMedCrossRef Lodise TP, Graves J, Evans A, et al. Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin. Antimicrob Agents Chemother 2008; 52: 3315–20PubMedCrossRef
146.
Zurück zum Zitat Graber CJ, Wong MK, Carleton HA, et al. Intermediate vancomycin susceptibility in a community-associated MRSA clone. Emerg Infect Dis 2007; 13: 491–3PubMedCrossRef Graber CJ, Wong MK, Carleton HA, et al. Intermediate vancomycin susceptibility in a community-associated MRSA clone. Emerg Infect Dis 2007; 13: 491–3PubMedCrossRef
147.
Zurück zum Zitat Chua T, Moore CL, Perri MB, et al. Molecular epidemiology of methicillin-resistant Staphylococcus aureus bloodstream isolates in urban Detroit. J Clin Microbiol 2008; 2345–52 Chua T, Moore CL, Perri MB, et al. Molecular epidemiology of methicillin-resistant Staphylococcus aureus bloodstream isolates in urban Detroit. J Clin Microbiol 2008; 2345–52
148.
Zurück zum Zitat Hidayat LK, Hsu DI, Quist R, et al. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections. Arch Intern Med 2006; 166: 2138–44PubMedCrossRef Hidayat LK, Hsu DI, Quist R, et al. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections. Arch Intern Med 2006; 166: 2138–44PubMedCrossRef
149.
Zurück zum Zitat Silverman JA, Perlmutter NG, Shapiro HM. Correlation of daptomycin bactericidal activity and membrane depolarization in Staphylococcus aureus. Antimicrob Agents Chemother 2003; 47: 2538–44PubMedCrossRef Silverman JA, Perlmutter NG, Shapiro HM. Correlation of daptomycin bactericidal activity and membrane depolarization in Staphylococcus aureus. Antimicrob Agents Chemother 2003; 47: 2538–44PubMedCrossRef
150.
Zurück zum Zitat Richter SS, Kealey DE, Murray CT, et al. The in vitro activity of daptomycin against Staphylococcus aureus and Enterococcus species. J Antimicrob Chemother 2003; 52: 123–7PubMedCrossRef Richter SS, Kealey DE, Murray CT, et al. The in vitro activity of daptomycin against Staphylococcus aureus and Enterococcus species. J Antimicrob Chemother 2003; 52: 123–7PubMedCrossRef
151.
Zurück zum Zitat Critchley IA, Draghi DC, Sahm DF, et al. Activity of daptomycin against susceptible and multidrug-resistant gram-positive pathogens collected in the SECURE study (Europe) during 2000–2001. J Antimicrob Chemother 2003; 51: 639–49PubMedCrossRef Critchley IA, Draghi DC, Sahm DF, et al. Activity of daptomycin against susceptible and multidrug-resistant gram-positive pathogens collected in the SECURE study (Europe) during 2000–2001. J Antimicrob Chemother 2003; 51: 639–49PubMedCrossRef
152.
Zurück zum Zitat Mangali A, Bica I, Snydman R, et al. Daptomycin-resistant methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis 2005; 40: 1058–60CrossRef Mangali A, Bica I, Snydman R, et al. Daptomycin-resistant methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis 2005; 40: 1058–60CrossRef
153.
Zurück zum Zitat Marty FM, Yeh WW, Wennersten CB, et al. Emergence of a clinical daptomycin-resistant Staphylococcus aureus isolate during treatment of methicillin-resistant Staphylococcus aureus bacteremia and osteomyelitis. J Clin Microbiol 2006; 44: 595–7PubMedCrossRef Marty FM, Yeh WW, Wennersten CB, et al. Emergence of a clinical daptomycin-resistant Staphylococcus aureus isolate during treatment of methicillin-resistant Staphylococcus aureus bacteremia and osteomyelitis. J Clin Microbiol 2006; 44: 595–7PubMedCrossRef
154.
Zurück zum Zitat Pillai SK, Gold HS, Sakoulas G, et al. Daptomycin nonsusceptibility in Staphylococcus aureus with reduced vancomycin susceptibility is independent of alterations in MprF. Antimicrob Agents Chemother 2007; 51: 2223–5PubMedCrossRef Pillai SK, Gold HS, Sakoulas G, et al. Daptomycin nonsusceptibility in Staphylococcus aureus with reduced vancomycin susceptibility is independent of alterations in MprF. Antimicrob Agents Chemother 2007; 51: 2223–5PubMedCrossRef
155.
Zurück zum Zitat Huang Y, Hsiao C, Liao C, et al. Bacteremia and infective endocarditis caused by a non-daptomycin-susceptible, vancomycin-intermediate, and methicillin-resistant Staphylococcus aureus strain in Taiwan. J Clin Microbiol 2008; 46: 1132–6PubMedCrossRef Huang Y, Hsiao C, Liao C, et al. Bacteremia and infective endocarditis caused by a non-daptomycin-susceptible, vancomycin-intermediate, and methicillin-resistant Staphylococcus aureus strain in Taiwan. J Clin Microbiol 2008; 46: 1132–6PubMedCrossRef
156.
Zurück zum Zitat Sakoulas G, Rose W, Rybak MJ, et al. Evaluation of endocarditis caused by methicillin-susceptible Staphylococcus aureus developing nonsusceptibility to daptomycin. J Clin Microbiol 2008; 46: 220–4PubMedCrossRef Sakoulas G, Rose W, Rybak MJ, et al. Evaluation of endocarditis caused by methicillin-susceptible Staphylococcus aureus developing nonsusceptibility to daptomycin. J Clin Microbiol 2008; 46: 220–4PubMedCrossRef
157.
Zurück zum Zitat Murthy MH, Olson ME, Wickert RW, et al. Daptomycin non-susceptible methicillin-resistant Staphylococcus aureus USA 300 isolate. J Med Microbiol 2008; 57: 1036–8PubMedCrossRef Murthy MH, Olson ME, Wickert RW, et al. Daptomycin non-susceptible methicillin-resistant Staphylococcus aureus USA 300 isolate. J Med Microbiol 2008; 57: 1036–8PubMedCrossRef
158.
Zurück zum Zitat Arbeit RD, Maki D, Tally FP, et al. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin Infect Dis 2004; 38: 1673–81PubMedCrossRef Arbeit RD, Maki D, Tally FP, et al. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin Infect Dis 2004; 38: 1673–81PubMedCrossRef
159.
Zurück zum Zitat Fowler Jr VG, Boucher HW, Corey GR, et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med 2006; 355: 653–65PubMedCrossRef Fowler Jr VG, Boucher HW, Corey GR, et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med 2006; 355: 653–65PubMedCrossRef
160.
Zurück zum Zitat Lamp KC, Friedrick LV. Clinical experience with daptomycin for the treatment of osteomyelitis in patients with post-therapy follow-up. 46th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2006 Sep 27–30; San Francisco (CA), L-1557 Lamp KC, Friedrick LV. Clinical experience with daptomycin for the treatment of osteomyelitis in patients with post-therapy follow-up. 46th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2006 Sep 27–30; San Francisco (CA), L-1557
161.
Zurück zum Zitat Finney MS, Crank CW, Segreti J. Use of daptomycin to treat drug-resistant gram-positive bone and joint infections. Curr Med Res Opin 2005; 21: 1923–26PubMedCrossRef Finney MS, Crank CW, Segreti J. Use of daptomycin to treat drug-resistant gram-positive bone and joint infections. Curr Med Res Opin 2005; 21: 1923–26PubMedCrossRef
162.
Zurück zum Zitat Forrest G, Donovan B, Lamp K, et al. Daptomycin use in patients with septic arthritis: post-marketing experience from CORE 2005. 46th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2006 Sep 27–30; San Francisco (CA), A-1556 Forrest G, Donovan B, Lamp K, et al. Daptomycin use in patients with septic arthritis: post-marketing experience from CORE 2005. 46th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2006 Sep 27–30; San Francisco (CA), A-1556
163.
Zurück zum Zitat Rao N, Regalla DM. Uncertain efficacy of daptomycin for prosthetic joint infections: a prospective case series. Clin Orthop Relat Res 2006; 451: 34–7PubMedCrossRef Rao N, Regalla DM. Uncertain efficacy of daptomycin for prosthetic joint infections: a prospective case series. Clin Orthop Relat Res 2006; 451: 34–7PubMedCrossRef
164.
Zurück zum Zitat Silverman JA, Mortin LI, Vanpraagh AD, et al. Inhibition of daptomycin by pulmonary surfactant: in vitro modeling and clinical impact. J Infect Dis 2005; 191: 2149–52PubMedCrossRef Silverman JA, Mortin LI, Vanpraagh AD, et al. Inhibition of daptomycin by pulmonary surfactant: in vitro modeling and clinical impact. J Infect Dis 2005; 191: 2149–52PubMedCrossRef
165.
Zurück zum Zitat Wunderink RG, Rello J, Cammarata SK, et al. Linezolid vs vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia. Chest 2003; 124: 1789–97PubMedCrossRef Wunderink RG, Rello J, Cammarata SK, et al. Linezolid vs vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia. Chest 2003; 124: 1789–97PubMedCrossRef
166.
Zurück zum Zitat Cruciani M, Gattie G, Lazzarini L, et al. Penetration of vancomycin into human lung tissue. J Antimicrob Chemother 1996; 38: 865–9PubMedCrossRef Cruciani M, Gattie G, Lazzarini L, et al. Penetration of vancomycin into human lung tissue. J Antimicrob Chemother 1996; 38: 865–9PubMedCrossRef
167.
Zurück zum Zitat Honeybourne D, Tobin C, Jevons G, et al. Intrapulmonary penetration of linezolid. J Antimicrob Chemother 2003; 51: 1431–4PubMedCrossRef Honeybourne D, Tobin C, Jevons G, et al. Intrapulmonary penetration of linezolid. J Antimicrob Chemother 2003; 51: 1431–4PubMedCrossRef
168.
Zurück zum Zitat Boselli E, Breilh D, Rimmelé T, et al. Pharmacokinetics and intrapulmonary concentrations of linezolid administered to critically ill patients with ventilator-associated pneumonia. Crit Care Med 2005; 33: 1529–33PubMedCrossRef Boselli E, Breilh D, Rimmelé T, et al. Pharmacokinetics and intrapulmonary concentrations of linezolid administered to critically ill patients with ventilator-associated pneumonia. Crit Care Med 2005; 33: 1529–33PubMedCrossRef
169.
Zurück zum Zitat Wunderink RG, Mendelson MH, Somero MS, et al. Early microbiological response to linezolid versus vancomycin in ventilator-associated pneumonia due to methicillinresistant Staphylococcus aureus. Chest 2008; 134: 1200–7PubMedCrossRef Wunderink RG, Mendelson MH, Somero MS, et al. Early microbiological response to linezolid versus vancomycin in ventilator-associated pneumonia due to methicillinresistant Staphylococcus aureus. Chest 2008; 134: 1200–7PubMedCrossRef
170.
Zurück zum Zitat Stevens DL, Ma Y, Salmi DB, et al. Impact of antibiotics on expression of virulence-associated exotoxins genes in methicillin-sensitive and methicillin-resistant Staphylococcus aureus. J Infect Dis 2007; 195: 202–11PubMedCrossRef Stevens DL, Ma Y, Salmi DB, et al. Impact of antibiotics on expression of virulence-associated exotoxins genes in methicillin-sensitive and methicillin-resistant Staphylococcus aureus. J Infect Dis 2007; 195: 202–11PubMedCrossRef
171.
Zurück zum Zitat Shorr AF, Kunkel MJ, Kollef M. Linezolid versus vancomycin for Staphylococcus aureus bacteraemia: pooled analysis of randomized studies. J Antimicrob Chemother 2005; 56: 923–9PubMedCrossRef Shorr AF, Kunkel MJ, Kollef M. Linezolid versus vancomycin for Staphylococcus aureus bacteraemia: pooled analysis of randomized studies. J Antimicrob Chemother 2005; 56: 923–9PubMedCrossRef
172.
Zurück zum Zitat Wilcox MH, Tack KJ, Bouza E, et al. Complicated skin and skin-structure infections and catheter-related bloodstream infections: noninferiority of linezolid in a phase 3 study. Clin Infect Dis 2009; 48: 203–12PubMedCrossRef Wilcox MH, Tack KJ, Bouza E, et al. Complicated skin and skin-structure infections and catheter-related bloodstream infections: noninferiority of linezolid in a phase 3 study. Clin Infect Dis 2009; 48: 203–12PubMedCrossRef
173.
Zurück zum Zitat Wu VC, Wang YT, Wang CY, et al. High frequency of linezolid-associated thrombocytopenia and anemia among patients with end-stage renal disease. Clin Infect Dis 2006; 42: 66–72PubMedCrossRef Wu VC, Wang YT, Wang CY, et al. High frequency of linezolid-associated thrombocytopenia and anemia among patients with end-stage renal disease. Clin Infect Dis 2006; 42: 66–72PubMedCrossRef
174.
Zurück zum Zitat Lawrence KR, Adra M, Gillman PK. Serotonin toxicity associated with the use of linezolid: a review of postmarketing data. Clin Infect Dis 2006; 42: 1578–83PubMedCrossRef Lawrence KR, Adra M, Gillman PK. Serotonin toxicity associated with the use of linezolid: a review of postmarketing data. Clin Infect Dis 2006; 42: 1578–83PubMedCrossRef
175.
Zurück zum Zitat Taylor JJ, Wilson JW, Estes LL. Linezolid and serotonergic drug interactions: a retrospective survey. Clin Infect Dis 2006; 43: 180–7PubMedCrossRef Taylor JJ, Wilson JW, Estes LL. Linezolid and serotonergic drug interactions: a retrospective survey. Clin Infect Dis 2006; 43: 180–7PubMedCrossRef
176.
Zurück zum Zitat Lee E, Burger S, Shah J, et al. Linezolid-associated toxic optic neuropathy: a report of 2 cases. Clin Infect Dis 2003; 37: 1389–91PubMedCrossRef Lee E, Burger S, Shah J, et al. Linezolid-associated toxic optic neuropathy: a report of 2 cases. Clin Infect Dis 2003; 37: 1389–91PubMedCrossRef
177.
Zurück zum Zitat Frippiat F, Bergiers C, Michel C, et al. Severe bilateral optic neuritis associated with prolonged linezolid therapy. J Antimicrob Chemother 2004; 53: 1114–5PubMedCrossRef Frippiat F, Bergiers C, Michel C, et al. Severe bilateral optic neuritis associated with prolonged linezolid therapy. J Antimicrob Chemother 2004; 53: 1114–5PubMedCrossRef
178.
Zurück zum Zitat Palenzuela L, Hahn NM, Nelson Jr RP, et al. Does linezolid cause lactic acidosis by inhibiting mitochondrial protein synthesis? Clin Infect Dis 2005; 40: e113–6PubMedCrossRef Palenzuela L, Hahn NM, Nelson Jr RP, et al. Does linezolid cause lactic acidosis by inhibiting mitochondrial protein synthesis? Clin Infect Dis 2005; 40: e113–6PubMedCrossRef
179.
Zurück zum Zitat Leclerq R, Courvalin P. Bacterial resistance to macrolides, lincosamide, and streptogramin antibiotics by target modification. Antimicrob Agents Chemother 1991; 35: 1267–72CrossRef Leclerq R, Courvalin P. Bacterial resistance to macrolides, lincosamide, and streptogramin antibiotics by target modification. Antimicrob Agents Chemother 1991; 35: 1267–72CrossRef
180.
Zurück zum Zitat Drew RH, Perfect JR, Srinath L, et al. Treatment of methicillin-resistant Staphylococcus aureus infections with quinupristin-dalfopristin in patients intolerant of or failing prior therapy. J Antimicrob Chemother 2000; 46: 775–84PubMedCrossRef Drew RH, Perfect JR, Srinath L, et al. Treatment of methicillin-resistant Staphylococcus aureus infections with quinupristin-dalfopristin in patients intolerant of or failing prior therapy. J Antimicrob Chemother 2000; 46: 775–84PubMedCrossRef
181.
Zurück zum Zitat Olsen KM, Rebuck JA, Rupp ME. Arthralgias and myalgias related to quinupristin-dalfopristin administration. Clin Infect Dis 2001; 32: e83–6PubMedCrossRef Olsen KM, Rebuck JA, Rupp ME. Arthralgias and myalgias related to quinupristin-dalfopristin administration. Clin Infect Dis 2001; 32: e83–6PubMedCrossRef
182.
Zurück zum Zitat Projan SJ. Preclinical pharmacology of GAR-936, a novel glycylcycline antibacterial agent. Pharmacotherapy 2000; 20: 219S–23SPubMedCrossRef Projan SJ. Preclinical pharmacology of GAR-936, a novel glycylcycline antibacterial agent. Pharmacotherapy 2000; 20: 219S–23SPubMedCrossRef
183.
Zurück zum Zitat Noskin GA. Tigecycline: a new glycylcycline for treatment of serious infections. Clin Infect Dis 2005; 41: S303–14PubMedCrossRef Noskin GA. Tigecycline: a new glycylcycline for treatment of serious infections. Clin Infect Dis 2005; 41: S303–14PubMedCrossRef
184.
Zurück zum Zitat Meagher AK, Ambrose PG, Grasela TH, et al. The pharmacokinetic and pharmocodynamic profile of tigecycline. Clin Infect Dis 2005; 41: S333–40PubMedCrossRef Meagher AK, Ambrose PG, Grasela TH, et al. The pharmacokinetic and pharmocodynamic profile of tigecycline. Clin Infect Dis 2005; 41: S333–40PubMedCrossRef
185.
Zurück zum Zitat Ellis-Grosse EJ, Babinchak T, Dartois N, et al. The efficacy and safety of tigecycline in the treatment of skin and skinstructure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonem. Clin Infect Dis 2005; 41: S341–53PubMedCrossRef Ellis-Grosse EJ, Babinchak T, Dartois N, et al. The efficacy and safety of tigecycline in the treatment of skin and skinstructure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonem. Clin Infect Dis 2005; 41: S341–53PubMedCrossRef
186.
Zurück zum Zitat McAleese F, Murphy E, Babinchak T, et al. Use of ribotyping to retrospectively identify methicillin-resistant Staphylococcus aureus isolates from phase 3 clinical trials for tigecycline that are genotypically related to community-associated isolates. Antimicrob Agents Chemother 2005; 49: 4521–9PubMedCrossRef McAleese F, Murphy E, Babinchak T, et al. Use of ribotyping to retrospectively identify methicillin-resistant Staphylococcus aureus isolates from phase 3 clinical trials for tigecycline that are genotypically related to community-associated isolates. Antimicrob Agents Chemother 2005; 49: 4521–9PubMedCrossRef
187.
Zurück zum Zitat Bogdanovich T, Ednie LM, Shapiro S, et al. Antistaphylococcal activity of ceftobiprole, a new broadspectrum cephalosporin. Antimicrob Agents Chemother 2005; 49: 4210–9PubMedCrossRef Bogdanovich T, Ednie LM, Shapiro S, et al. Antistaphylococcal activity of ceftobiprole, a new broadspectrum cephalosporin. Antimicrob Agents Chemother 2005; 49: 4210–9PubMedCrossRef
188.
Zurück zum Zitat Leonard SN, Cheung CM, Rybak MJ. Activities of ceftobiprole, linezolid, vancomycin, and daptomycin against community-associated and hospital-associated methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2008; 52: 2974–6PubMedCrossRef Leonard SN, Cheung CM, Rybak MJ. Activities of ceftobiprole, linezolid, vancomycin, and daptomycin against community-associated and hospital-associated methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2008; 52: 2974–6PubMedCrossRef
189.
Zurück zum Zitat Blumberg HM, Rimland D, Carroll DJ, et al. Rapid development of ciprofloxacin resistance in methicillinsusceptible and -resistant Staphylococcus aureus. J Infect Dis 1991; 163: 1279–85PubMedCrossRef Blumberg HM, Rimland D, Carroll DJ, et al. Rapid development of ciprofloxacin resistance in methicillinsusceptible and -resistant Staphylococcus aureus. J Infect Dis 1991; 163: 1279–85PubMedCrossRef
190.
Zurück zum Zitat Peterson LR, Quick JN, Jensen B, et al. Emergence of ciprofloxacin resistance in nosocomial methicillin-resistant Staphylococcus aureus isolates: resistance during ciprofloxacin plus rifampin therapy for methicillin-resistant S. aureus colonization. Arch Intern Med 1990; 150: 2151–5PubMedCrossRef Peterson LR, Quick JN, Jensen B, et al. Emergence of ciprofloxacin resistance in nosocomial methicillin-resistant Staphylococcus aureus isolates: resistance during ciprofloxacin plus rifampin therapy for methicillin-resistant S. aureus colonization. Arch Intern Med 1990; 150: 2151–5PubMedCrossRef
191.
Zurück zum Zitat Eng RHK, Smith SM, Buccini FJ, et al. Differences in ability of cell-wall antibiotics to suppress emergence of rifampicin resistance in Staphylococcus aureus. J Antimicrob Chemother 1985; 15: 201–7PubMedCrossRef Eng RHK, Smith SM, Buccini FJ, et al. Differences in ability of cell-wall antibiotics to suppress emergence of rifampicin resistance in Staphylococcus aureus. J Antimicrob Chemother 1985; 15: 201–7PubMedCrossRef
192.
Zurück zum Zitat Iyer S, Jones DH. Community-acquired methicillinresistant Staphylococcus aureus skin infection: a retrospective analysis of clinical presentation and treatment of a local outbreak. J Am Acad Dermatol 2004; 50: 854–8PubMedCrossRef Iyer S, Jones DH. Community-acquired methicillinresistant Staphylococcus aureus skin infection: a retrospective analysis of clinical presentation and treatment of a local outbreak. J Am Acad Dermatol 2004; 50: 854–8PubMedCrossRef
193.
Zurück zum Zitat Lin G, Credito K, Ednie LM, et al. Antistaphylococcal activity of dalbavancin, and experimental glycopeptide. Antimicrob Agents Chemother 2005; 49: 770–2PubMedCrossRef Lin G, Credito K, Ednie LM, et al. Antistaphylococcal activity of dalbavancin, and experimental glycopeptide. Antimicrob Agents Chemother 2005; 49: 770–2PubMedCrossRef
194.
Zurück zum Zitat Jauregi LE, Babazadeh S, Seltzer E, et al. Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections. Clin Infect Dis 2005; 41: 1407–15CrossRef Jauregi LE, Babazadeh S, Seltzer E, et al. Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections. Clin Infect Dis 2005; 41: 1407–15CrossRef
195.
Zurück zum Zitat Raad I, Darouiche R, Vazquez J, et al. Efficacy and safety of weekly dalbavancin therapy for catheter-related bloodstream infection caused by Gram-positive pathogens. Clin Infect Dis 2005; 40: 374–80PubMedCrossRef Raad I, Darouiche R, Vazquez J, et al. Efficacy and safety of weekly dalbavancin therapy for catheter-related bloodstream infection caused by Gram-positive pathogens. Clin Infect Dis 2005; 40: 374–80PubMedCrossRef
196.
Zurück zum Zitat Kanafani ZA. Telavancin: a new lipoglycopeptide with multiple mechanisms of action. Expert Rev Anti Infect Ther 2006; 4: 743–9PubMedCrossRef Kanafani ZA. Telavancin: a new lipoglycopeptide with multiple mechanisms of action. Expert Rev Anti Infect Ther 2006; 4: 743–9PubMedCrossRef
197.
Zurück zum Zitat Stryjewski M, Chu VH, O’Riordan W, et al. Telavancin versus standard therapy for treatment of complicated skin and skin structure infections caused by Gram-positive bacteria: FAST 2 study. Antimicrob Agents Chemother 2006; 50: 862–7PubMedCrossRef Stryjewski M, Chu VH, O’Riordan W, et al. Telavancin versus standard therapy for treatment of complicated skin and skin structure infections caused by Gram-positive bacteria: FAST 2 study. Antimicrob Agents Chemother 2006; 50: 862–7PubMedCrossRef
198.
Zurück zum Zitat Fowler Jr VG, Rude TH, Nelson CL, et al. Activity of telavancin against Staphylococcus aureus isolates carrying the Panton-Valentine leukocidin gene in the ATLAS studies [abstract 847]. In: Program and abstracts of the 17th European Congress of Clinical Microbiology and Infectious Diseases (Munich). Oxford: Blackwell Publishing, 2007 Fowler Jr VG, Rude TH, Nelson CL, et al. Activity of telavancin against Staphylococcus aureus isolates carrying the Panton-Valentine leukocidin gene in the ATLAS studies [abstract 847]. In: Program and abstracts of the 17th European Congress of Clinical Microbiology and Infectious Diseases (Munich). Oxford: Blackwell Publishing, 2007
199.
Zurück zum Zitat Giamarellou H, O’Riordon W, Harris H, et al. Phase 3 trial comparing 3–7 days of oritavancin vs. 10–14 days of vancomycin/cephalexin in the treatment of patients with complicated skin and skin structure infections (cSSSI) [abstract]. In: Program and abstracts of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (Chicago). Washington, DC: American Society for Microbiology, 2003 Giamarellou H, O’Riordon W, Harris H, et al. Phase 3 trial comparing 3–7 days of oritavancin vs. 10–14 days of vancomycin/cephalexin in the treatment of patients with complicated skin and skin structure infections (cSSSI) [abstract]. In: Program and abstracts of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (Chicago). Washington, DC: American Society for Microbiology, 2003
200.
Zurück zum Zitat Wasilewski M, Dish D, McGill J, et al. Equivalence of shorter course of therapy with oritavancin vs. vancomycin/cephalexin in complicated skin and skin structure infections (cSSSI) [abstract UL-18]. In: Program and abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (Chicago). Washington, DC: American Society for Microbiology, 2001 Wasilewski M, Dish D, McGill J, et al. Equivalence of shorter course of therapy with oritavancin vs. vancomycin/cephalexin in complicated skin and skin structure infections (cSSSI) [abstract UL-18]. In: Program and abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (Chicago). Washington, DC: American Society for Microbiology, 2001
201.
Zurück zum Zitat Kim SJ, Cegelski L, Stueber D, et al. Oritavancin exhibits dual mode of action to inhibit cell-wall biosynthesis in Staphylococcus aureus. J Mol Biol 2008; 14: 281–93CrossRef Kim SJ, Cegelski L, Stueber D, et al. Oritavancin exhibits dual mode of action to inhibit cell-wall biosynthesis in Staphylococcus aureus. J Mol Biol 2008; 14: 281–93CrossRef
202.
Zurück zum Zitat Ward KE, Mersfelder TL, LaPlante KL. Oritavancin: an investigational glycopeptide antibiotic. Expert Opin Investig Drugs 2006; 15: 417–29PubMedCrossRef Ward KE, Mersfelder TL, LaPlante KL. Oritavancin: an investigational glycopeptide antibiotic. Expert Opin Investig Drugs 2006; 15: 417–29PubMedCrossRef
203.
Zurück zum Zitat Cerexa, Inc. Comparative study of seftaroline vs. vancomycin plus aztreonam in adult subjects with complicated skin infections [ClinicalTrials.gov identifier NCT 00423657]. US National Institutes of Health, Clinical Trials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2009 Apr 2] Cerexa, Inc. Comparative study of seftaroline vs. vancomycin plus aztreonam in adult subjects with complicated skin infections [ClinicalTrials.gov identifier NCT 00423657]. US National Institutes of Health, Clinical Trials.gov [online]. Available from URL: http://​www.​clinicaltrials.​gov [Accessed 2009 Apr 2]
204.
Zurück zum Zitat Cerexa, Inc. Comparative study of ceftaroline vs. vancomycin plus aztreonam in adult subjects with complicated skin infections (cSSSI) [ClinicalTrials.gov identifier NCT00424190]. US National Institutes of Health, Clinical Trials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2009 Apr 2] Cerexa, Inc. Comparative study of ceftaroline vs. vancomycin plus aztreonam in adult subjects with complicated skin infections (cSSSI) [ClinicalTrials.gov identifier NCT00424190]. US National Institutes of Health, Clinical Trials.gov [online]. Available from URL: http://​www.​clinicaltrials.​gov [Accessed 2009 Apr 2]
205.
Zurück zum Zitat Cerexa, Inc. Efficacy and safety of ceftaroline versus linezolid in subjects with complicated skin and skin structure infections [ClinicalTrials.gov identifier NCT00633152]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2009 Apr 2] Cerexa, Inc. Efficacy and safety of ceftaroline versus linezolid in subjects with complicated skin and skin structure infections [ClinicalTrials.gov identifier NCT00633152]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://​www.​clinicaltrials.​gov [Accessed 2009 Apr 2]
206.
Zurück zum Zitat Arpida AG. Study of intravenous (I.V.) iclaprim versus linezolid in complicated skin and skin structure infections [cSSSI] (ASSIST-2) [ClinicalTrials.gov identifier NCT 00303550]. US National Institutes of Health, Clinical Trials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2009 Apr 2] Arpida AG. Study of intravenous (I.V.) iclaprim versus linezolid in complicated skin and skin structure infections [cSSSI] (ASSIST-2) [ClinicalTrials.gov identifier NCT 00303550]. US National Institutes of Health, Clinical Trials.gov [online]. Available from URL: http://​www.​clinicaltrials.​gov [Accessed 2009 Apr 2]
207.
Zurück zum Zitat Arpida AG. Phase 3 safety and efficacy study of I.V. iclaprim v linezolid in cSSSI (ASSIST-1) [ClinicalTrials.gov identifier NCT00299520]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2009 Apr 2] Arpida AG. Phase 3 safety and efficacy study of I.V. iclaprim v linezolid in cSSSI (ASSIST-1) [ClinicalTrials.gov identifier NCT00299520]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://​www.​clinicaltrials.​gov [Accessed 2009 Apr 2]
208.
Zurück zum Zitat Arpida AG. Clinical efficacy of intravenous iclaprim versus vancomycin in the treatment of hospital-acquired, ventilator-associated, or health-care-associated pneumonia [ClinicalTrials.gov identifier NCT00543608]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2009 Apr 2] Arpida AG. Clinical efficacy of intravenous iclaprim versus vancomycin in the treatment of hospital-acquired, ventilator-associated, or health-care-associated pneumonia [ClinicalTrials.gov identifier NCT00543608]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://​www.​clinicaltrials.​gov [Accessed 2009 Apr 2]
209.
Zurück zum Zitat Lee MC, Rios AM, Aten MF, et al. Management and outcome of children with skin and soft-tissue abscesses caused by community-acquired methicillin-resistant Staphylococcus aureus. Pediatr Infect Dis J 2004; 23: 123–7PubMedCrossRef Lee MC, Rios AM, Aten MF, et al. Management and outcome of children with skin and soft-tissue abscesses caused by community-acquired methicillin-resistant Staphylococcus aureus. Pediatr Infect Dis J 2004; 23: 123–7PubMedCrossRef
210.
Zurück zum Zitat Giordano PA, Elston D, Akinlade BK, et al. Cefdinir vs cephalexin for mild to moderate uncomplicated skin and skin structure infections in adolescents and adults. Curr Med Res Opin 2006; 22: 2419–28PubMedCrossRef Giordano PA, Elston D, Akinlade BK, et al. Cefdinir vs cephalexin for mild to moderate uncomplicated skin and skin structure infections in adolescents and adults. Curr Med Res Opin 2006; 22: 2419–28PubMedCrossRef
211.
Zurück zum Zitat Rajendran PM, Young D, Maurer T, et al. Randomized, double-blind, placebo-controlled trial of cephalexin for treatment of uncomplicated skin abscesses in a population at risk for community-acquired methicillin-resistant Staphylococcus aureus infection. Antimicrob Agents Chemother 2007; 51: 4044–8PubMedCrossRef Rajendran PM, Young D, Maurer T, et al. Randomized, double-blind, placebo-controlled trial of cephalexin for treatment of uncomplicated skin abscesses in a population at risk for community-acquired methicillin-resistant Staphylococcus aureus infection. Antimicrob Agents Chemother 2007; 51: 4044–8PubMedCrossRef
212.
Zurück zum Zitat Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft-tissue infections. Clin Infect Dis 2005; 41: 1373–406PubMedCrossRef Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft-tissue infections. Clin Infect Dis 2005; 41: 1373–406PubMedCrossRef
213.
Zurück zum Zitat Chambers HF, Moellering Jr RC, Kamitsuka P. Management of skin and soft-tissue infection. N Engl J Med 2008; 359: 1063–7PubMedCrossRef Chambers HF, Moellering Jr RC, Kamitsuka P. Management of skin and soft-tissue infection. N Engl J Med 2008; 359: 1063–7PubMedCrossRef
214.
216.
Zurück zum Zitat Miller LG, Diep BA. Colonization, fomites, and virulence: rethinking the pathogenesis of community-associated methicillin-resistant Staphylococcus aureus infection. Clin Infect Dis 2008; 46: 752–60PubMedCrossRef Miller LG, Diep BA. Colonization, fomites, and virulence: rethinking the pathogenesis of community-associated methicillin-resistant Staphylococcus aureus infection. Clin Infect Dis 2008; 46: 752–60PubMedCrossRef
Metadaten
Titel
Community-Associated Meticillin-Resistant Staphylococcus aureus Infections
Epidemiology, Recognition and Management
verfasst von
Dr Mukesh Patel
Publikationsdatum
01.04.2009
Verlag
Springer International Publishing
Erschienen in
Drugs / Ausgabe 6/2009
Print ISSN: 0012-6667
Elektronische ISSN: 1179-1950
DOI
https://doi.org/10.2165/00003495-200969060-00004

Weitere Artikel der Ausgabe 6/2009

Drugs 6/2009 Zur Ausgabe

Review Article

Endometriosis

Adis Drug Profile

Fesoterodine

Adis Drug Evaluation

Ferric Carboxymaltose